

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number  
**WO 02/085402 A1**

(51) International Patent Classification<sup>7</sup>: A61K 38/00,  
38/16

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,  
YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US02/12891

(22) International Filing Date: 24 April 2002 (24.04.2002)

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:  
60/286,240 24 April 2001 (24.04.2001) US

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; 32 Fruit Street, Boston, MA 02114 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor: PODOLSKY, Daniel, K.; 157 Edmunds Road, Wellesley Hills, MA 02181 (US).

(74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,



WO 02/085402 A1

(54) Title: METHODS AND COMPOSITIONS FOR TREATING ORAL AND EOSOPHAGEAL LESIONS

(57) Abstract: The invention features methods and compositions for treating or preventing lesions of the upper elementary canal, particularly oral aphthous or mucositis lesions. Intestinal trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents.

5

## METHODS AND COMPOSITIONS FOR TREATING ORAL AND ESOPHAGEAL LESIONS

### Field of the Invention

This invention provides methods and compositions for treating lesions of  
10 the upper alimentary canal including the oral cavity and esophagus.

### Background of the Invention

Oral mucositis is the destruction of the oral mucosal epithelium which results in erythema, ulcerations, and pain in the oral cavity. Mucositis often arises  
15 as a complication of antineoplastic therapy such as cancer chemotherapy or radiotherapy. The painful ulcerative lesions of mucositis can cause patients to restrict their oral intake of food and liquids; as a result, they lose weight and suffer from dehydration. Severe mucositis can necessitate the de-escalation or the complete interruption of anti-neoplastic therapy. Chemotherapy or radiotherapy  
20 can also disrupt mucosal epithelium more distally in the gastrointestinal tract including the esophagus, stomach, and small and large intestines, resulting in pain and organ dysfunction (i.e., diarrhea).

The mucositis lesions are also sites of secondary infections, acting as portals of entry for endogenous oral microorganisms; a particularly serious  
25 concern in patients who are immunocompromised. Mucositis is therefore a significant risk factor for chronic debilitating local infections (e.g. yeast (*Candida*) infections) as well as life-threatening systemic infection (septicemia). Patients with mucositis and neutropenia have a relative risk of septicemia that is at least four times greater than that of individuals without mucositis.

30 Aphthous ulcers of the mouth (or aphthous stomatitis) are a common and painful problem; approximately 10% of the population suffers from these mouth sores at one time or another. The cause of outbreaks of aphthous sores are not

well understood, although they tend to be associated with stress and minor injury to the inside of the mouth. No satisfactory treatments are available, although topical application of steroids provides relief for some patients.

5

### Summary of the Invention

This invention features a method for treating a lesion of the upper alimentary canal in a mammal by administering to the mammal a therapeutically effective amount of an intestinal trefoil peptide. Preferably, the mammal is a human. In preferred embodiments, the intestinal trefoil peptide is spasmolytic polypeptide (SP), pS2, or intestinal trefoil factor (ITF). More preferably, the intestinal trefoil peptide is ITF.

Lesions of the upper alimentary canal such as mucositis, aphthous stomatitis, and gingivitis can be treated by the methods of this invention. Additionally, lesions of the upper alimentary canal that result from antineoplastic therapy (i.e., chemotherapy or radiotherapy), Behcet's Disease, biopsy, surgery, tumor resection, thermal or chemical burns, tooth extraction, trauma from any cause, or lesions caused by microbial (i.e., bacterial, viral, or fungal) infection are also amenable to treatment.

In preferred embodiments, the patient is also administered a second therapeutic agent. Preferred second therapeutic agents include anti-inflammatory agents, antibacterial agents (i.e., penicillins, cephalosporins, tetracyclines, or aminoglycosides), antifungal agents (i.e., nystatin or amphotericin B), antiviral agents (i.e., acyclovir), topical antiseptics (i.e., povidone-iodine), analgesics (i.e., lidocaine or benzocaine), or steroids (i.e., triamcinolone or hydrocortisone). Preferably, the second therapeutic agent is administered within 3 days, 1 day, 12 hours, 1 hour, or simultaneously with the intestinal trefoil peptide. The second therapeutic agent can be present in the same pharmaceutical composition as the intestinal trefoil peptide.

The invention also features pharmaceutical compositions suitable for delivering an intestinal trefoil peptide to the upper alimentary canal. Preferably, the pharmaceutical composition is an oral spray, an oral rinse (mouthwash), an ointment, a paste, a cream, a gel, chewing gum, a chewable tablet, a lozenge, or a 5 bioerodable film. In one embodiment, the pharmaceutical compositions use bioerodable microspheres to encapsulate one or more of the therapeutic agents. In preferred embodiments of an oral spray, rinse, ointment, paste, gel, or bioerodable film, a mucoadhesive or viscosity-enhancing agent is present.

In other preferred embodiments, the intestinal trefoil peptide of the 10 pharmaceutical composition is SP, pS2, or ITF. More preferably, the intestinal trefoil peptide is ITF. In other preferred embodiments, the pharmaceutical composition further contains a second therapeutic. Preferred second therapeutic agents include anti-inflammatory agents, antibacterial agents (i.e., penicillins, cephalosporins, tetracyclines, or aminoglycosides), antifungal agents (i.e., nystatin 15 or amphotericin B), antiviral agents (i.e., acyclovir), topical antiseptics (i.e., povidone-iodine), analgesics (i.e., lidocaine or benzocaine), or steroids (i.e., triamcinolone or hydrocortisone).

By "intestinal trefoil peptide" is meant all mammalian homologs of human spasmolytic polypeptide (SP; also known as TFF2), human pS2 (also known as 20 TFF1) and human intestinal trefoil factor (ITF; also known as TFF3), and biologically active fragments thereof. Homologs of the trefoil peptides have, preferably, 70% amino acid identity to the human sequence, more preferably 85% identity, most preferably 95%, or even 99% sequence identity. The length of comparison sequences will generally be at least about 10 amino acid residues, 25 usually at least 20 amino acid residues, more usually at least 30 amino acid residues, typically at least 45 amino acid residues, and preferably more than 60 amino acid residues.

The term "fragment" is meant to include polypeptides that are truncations or deletions of SP, pS2 and ITF. Preferably, the fragments have 70% amino acid 30 identity to the corresponding regions of the human polypeptide sequence. More

preferably, the fragments are 85% identical, most preferably 95%, or even 99% identical to the human polypeptide sequence to which they correspond. The length of comparison sequences will generally be at least about 10 amino acid residues, usually at least 20 amino acid residues, more usually at least 30 amino  
5 acid residues, typically at least 45 amino acid residues, and preferably more than 60 amino acid residues.

Preferable fragments contain four cysteine residues in any positions which correspond to the cysteines at positions 25, 35, 45, 50, 51, 62, or 71, of human ITF (Figure 1), or positions 31, 41, 51, 56, 57, 68, and 82 of human pS2 (Figure  
10 2). More preferably, fragments contain five cysteine residues at these positions. Most preferably, six, or even all seven cysteines are present.

Fragments of SP are meant to include truncations or deletions and preferably have 70% sequence identity to the corresponding human SP polypeptide sequence (Figure 3). More preferably, the fragments are 85%  
15 identical, most preferably 95%, or even 99% identical to the human polypeptide sequence. Preferably, active fragments contain at least four cysteine residues which correspond to positions 6, 8, 19, 29, 34, 35, 46, 58, 68, 78, 83, 84, 95, and 104 in the human SP polypeptide. More preferably, fragments contain six cysteines which correspond to these positions. Even more preferable are  
20 fragments that contain eight cysteines. Most preferable are fragments that contain cysteines at ten, twelve, or even, all fourteen positions.

It is recognized in the art that one function of the identified cysteine residues is to impart the characteristic three-loop (trefoil) structure to the protein. Accordingly, preferred fragments of ITF and pS2 have a least one loop structure,  
25 more preferably, the fragments have two loop structures, and most preferably, they have three loop structures. It is equally well recognized that the native SP polypeptide has a six loop confirmation. Preferable fragments contain at least two of these loop structures, more preferably, four loop structures are conserved, and most preferably, five, or even all six loop structures are present.

By "co-formulated" is meant any single pharmaceutical composition which contains two or more therapeutic or biologically active agents.

By "pharmaceutical preparation" or "pharmaceutical composition" is meant any composition which contains at least one therapeutically or biologically active agent and is suitable for administration to a patient. For the purposes of this invention, pharmaceutical compositions suitable for delivering a therapeutic to the upper alimentary canal include, but are not limited to solutions and suspensions delivered either as an oral spray or rinse, pastes, gels, chewable tablets, sublingual, gingival, or buccal wafers and films, chewing gum, lozenges, and other compositions designed to be retained in the mouth for an extended period of time. Any of these formulations can be prepared by well known and accepted methods of art. See, for example, Remington: The Science and Practice of Pharmacy, 19<sup>th</sup> edition, (ed. AR Gennaro), Mack Publishing Co., Easton, PA, 1995.

By "microsphere" is meant a bioerodable polymeric pharmaceutical delivery device having a diameter of 5-100  $\mu\text{m}$  and a hollow central core suitable for encapsulation of the therapeutic agent. Typically, the therapeutic agent is encapsulated at the time of microsphere formulation.

By "therapeutically effective amount" is meant an amount sufficient to provide medical benefit. When administering trefoil peptides to a human patient according to the methods described herein, a therapeutically effective amount is usually about 0.1-1000 mg of intestinal trefoil peptide per day. Preferably, the patient receives, 10 mg, 100 mg, 250 mg, or 750 mg of intestinal trefoil peptide each day. The total daily does can be divided into multiple individual doses.

By "upper alimentary canal" is meant the portion of the digestive system proximal to the cardiac sphincter (cardioesophageal sphincter) of the stomach. Specifically, the upper alimentary canal is meant to include the oral cavity and associated structures (e.g., the tongue, gingival and sublingual tissues, and the hard and soft palates) and the esophagus.

By "biologically active," when referring to an intestinal trefoil peptide, fragment, or homolog is meant any polypeptide that exhibits an activity common to its related, naturally occurring family member, and that the activity is common to the family of naturally occurring intestinal trefoil peptides. An example of a 5 biological activity common to the family of trefoil peptides is the ability to alter gastrointestinal motility in a mammal.

By "isolated DNA" is meant DNA that is free of the genes which, in the naturally-occurring genome of the organism from which the given DNA is derived, flank the DNA. Thus, the term "isolated DNA" encompasses, for 10 example, cDNA, cloned genomic DNA, and synthetic DNA.

By "treating" is meant administering a pharmaceutical composition for prophylactic and/or therapeutic purposes. The active ingredients of the pharmaceutical composition can treat the primary indication (i.e., epithelial lesion) or secondary symptoms (e.g., concomitant infection, pain, or 15 inflammation).

By "analgesic" is meant an agent which relieves pain by elevating the pain threshold without significantly disturbing the consciousness of the patient.

By "antimicrobial agent" is meant any compound that alters the growth of bacteria or fungi cells, or viruses whereby growth is prevented, stabilized, or 20 inhibited, or wherein the microbes are killed. In other words, the antimicrobial agents can be microbiocidal or microbiostatic.

By "thermal burn" is meant injury to or destruction of at least the epithelial cell layer caused by exposure to excessive temperature. Thermal burns of the upper alimentary canal are usually caused by ingestion of overly-heated foods and 25 liquids, or inhalation of super-heated air. Thermal burns are meant to include, but are not limited to, burns classified as first degree, second degree, and third degree burns.

By "chemical burn" is meant injury to or destruction of at least the epithelial cell layer caused by exposure to noxious chemicals. Typically, 30 chemical exposures of the upper alimentary canal are caused by inhalation or

ingestion.

By "antineoplastic therapy" is meant any treatment regimen used to treat cancer. Typical antineoplastic therapies include chemotherapy and radiation therapy.

5

#### Brief Description of Drawings

Figure 1 is the amino acid sequence of a human intestinal trefoil factor (ITF; Accession No. BAA95531; SEQ ID NO: 1).

10 Figure 2 is the amino acid sequence of a human pS2 protein (Accession No. NP\_003216; SEQ ID NO: 2).

Figure 3 is the amino acid sequence of human spasmolytic polypeptide (SP; Accession No. 1909187A; SEQ ID NO:3).

Figure 4 is a cDNA sequence encoding a human intestinal trefoil factor (SEQ ID NO: 4).

15 Figure 5 is a cDNA sequence encoding a human pS2 protein (SEQ ID NO: 5).

Figure 6 is a cDNA sequence encoding a human spasmolytic polypeptide (SEQ ID NO: 6).

20 Figure 7 is the nucleotide sequence of a gene encoding human intestinal trefoil factor (locus 10280533:52117-55412; SEQ ID NO: 7).

Figure 8 is the nucleotide sequence of a gene encoding human pS2 protein (locus 10280533:16511-21132; SEQ ID NO: 8).

Figure 9 is the nucleotide sequence of a gene encoding human spasmolytic polypeptide (locus 10280533:957-5208; SEQ ID NO: 9).

25

#### Detailed Description

The invention provides methods and compositions useful for the treatment of a wide range of lesions of the upper alimentary canal. The intestinal trefoil peptide therapy of this invention is particularly useful for treating epithelial lesions of the oral and esophageal mucosa, tongue, and gingival tissue.

Mammalian trefoil peptides were discovered in 1982. One of the mammalian trefoil peptides, human intestinal trefoil factor (ITF; TFF3), has been characterized extensively, and is described in U.S. Patent Nos. 6,063,755, and 6,221,840, hereby incorporated by reference. The other two known human 5 intestinal trefoil peptides are spasmolytic polypeptide (SP; TFF2) and pS2 (TFF1). Trefoil peptides, described extensively in the literature (e.g., Sands *et al.*, Annu. Rev. Physiol. 58: 253-273 (1996), hereby incorporated by reference), are expressed in the gastrointestinal tract and have a three-loop structure formed by intrachain disulfide bonds between conserved cysteine residues. These peptides 10 protect the intestinal tract from injury and can be used to treat intestinal tract disorders such as peptic ulcers and inflammatory bowel disease. Homologs of these human peptides have been found in a number of non-human animal species. All members of this protein family, both human and non-human, are referred to herein as trefoil peptides. Human ITF will be referred to most extensively in this 15 application; however, the activity of human ITF is common to each of the mammalian intestinal trefoil peptides.

We have discovered that epithelial lesions of the upper alimentary canal including the oral and esophageal mucosa, tongue, and gingival tissue can be treated by local administration of intestinal trefoil peptides. Thus, trefoil peptide 20 therapy, according to the methods of this invention, can be delivered in any pharmaceutical composition which is useful for delivering therapeutics to the upper alimentary canal.

### ***Pharmaceutical Preparations***

#### **Oral Sprays, Rinses, and Emulsions**

Spray systems are particularly useful for delivering therapeutics to the upper alimentary canal. Suitable spray delivery systems include both pressurized and non-pressurized (pump actuated) delivery devices. The intestinal trefoil peptide-containing solution, delivered as an oral spray, is preferably an aqueous 30 solution; however, organic and inorganic components, emulsifiers, excipients, and

agents that enhance the organoleptic properties (i.e., flavoring agents or odorants) may be included. Optionally, the solution may contain a preservative that prevents microbial growth (i.e., methyl paraben). Although water itself may make up the entire carrier, typical liquid spray formulations contain a co-solvent, for example, propylene glycol, corn syrup, glycerin, sorbitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients. In general, therefore, the compositions of this invention preferably contain from about 1-95% v/v and, most preferably, about 5-50% v/v, of the co-solvent. When prepared as an spray, patients typically self-administer 1-5 times per day. The spray delivery system is normally designed to deliver 50-100 µl per actuation, and therapy may require 1-5 actuations per dose. The rheological properties of the spray formulation are optimized to allow shear and atomization for droplet formation. Additionally, the spray delivery device is designed to create a droplet size which promotes retention on mucosal surfaces of the upper alimentary canal and minimize respiratory exposure.

Compositions suitable for oral sprays can also be formulated as an oral rinse or mouthwash. Administration of trefoil peptides using these formulations is typically done by swishing, gargling, or rinsing the oral cavity with the formulation. Optionally, these formulations can be swallowed, providing trefoil peptide therapy to the esophagus, stomach, and/or intestines. This delivery method is particularly useful for treating patients suffering related disorders of the intestinal epithelium. For example, patients receiving antineoplastic chemotherapy, in addition to oral mucositis, frequently develop more distal lesions of the gastrointestinal tract such as lesions of the gastric and intestinal epithelium. It is well known that intestinal trefoil peptides, particularly ITF, are stable at stomach pH. Thus, swallowing an intestinal trefoil peptide-containing solution designed primarily for treating oral mucositis may also benefit lesions of the lower alimentary canal (i.e., stomach and intestines).

In an alternative formulation, the intestinal trefoil peptides and/or other therapeutics can be encapsulated in bioerodible microspheres rather than being dissolved in the aqueous phase of the formulation. A wide variety of microencapsulation drug delivery systems have been developed and many share 5 similar polymeric compositions as used for bioerodible films (described below). Polymers commonly used in the formation of microspheres include, for example, poly- $\epsilon$ -caprolactone, poly( $\epsilon$ -caprolactone-Co-DL-lactic acid), poly(DL-lactic acid), poly(DL-lactic acid-Co-glycolic acid) and poly( $\epsilon$ -caprolactone-Co-glycolic acid) (see, for example, Pitt *et al.*, J. Pharm. Sci., 68:1534, 1979).

10 Microspheres can be made by procedures well known in the art including spray drying, coacervation, and emulsification (see for example Davis *et al.* Microsphere and Drug Therapy, Elsevier, 1984; Benoit *et al.* Biodegradable Microspheres: Advances in Production Technologies, Chapter 3, Ed. Benita, S, Dekker, New York, 1996; Microencapsulation and Related Drug Processes, Ed. 15 Deasy, Dekker, 1984, New York; U.S. Patent No. 6,365,187). Preferably, the microspheres are bioadhesive or are prepared in formulations containing a bioadhesive excipient.

Other technical features of the intestinal trefoil peptide-containing 20 solutions are easily modified to suit the specific pharmaceutical formulation and the clinical indication being treated. For example, the pH and osmolality of the formulation may be adjusted to confer trefoil peptide stability, while minimizing oral irritancy and sensitivity.

#### Ointments, Pastes, and Gels

25 Lesions of the oral and esophageal epithelium caused by trauma are amenable to trefoil peptide therapy delivered as an ointment, paste, or gel. The viscous nature of these types of preparations allows for direct application into the wound site. Optionally, the wound site can be covered with a dressing to retain the trefoil peptide-containing composition, protect the lesion from trauma, and/or 30 absorb exudate. As discussed further below, these preparations are particularly

useful to restore epithelial integrity following traumatic surgical procedures such as, for example, tooth extraction, tissue biopsy, or a tumor resection. Such viscous formulations may also have a local barrier effect thereby reducing irritation and pain.

5

### Mucoadhesives

A mucoadhesive excipient can be added to any of the previously described pharmaceutical compositions. The mucoadhesive formulations coat the upper alimentary canal providing protection, inhibiting irritation, and accelerating 10 healing of inflamed or damaged tissue. Mucoadhesive formulations also promote prolonged contact of the intestinal trefoil peptide with the mucosal epithelium. Mucoadhesive formulations suitable for use in pharmaceutical preparations delivered by mouth are well known in the art (e.g., U.S. Patent No. 5,458,879). Particularly useful mucoadhesives are hydrogels composed of about 0.05-20% of 15 a water-soluble polymer such as, for example, poly(ethylene oxide), poly(ethylene glycol), poly(vinyl alcohol), poly(vinyl pyrrolidine), poly(acrylic acid), poly(hydroxy ethyl methacrylate), hydroxyethyl ethyl cellulose, hydroxy ethyl cellulose, chitosan, and mixtures thereof. These polymeric formulations can also contain a dispersant such as sodium carboxymethyl cellulose (0.5-5.0%).

20 Other preferred mucoadhesive excipients for liquid compositions are ones that allow the composition to be administered as a flowable liquid but will cause the composition to gel in the upper alimentary canal, thereby providing a bioadhesive effect which acts to hold the therapeutic agents at the lesion site for an extended period of time. The anionic polysaccharides pectin and gellan are 25 examples of materials which when formulated into a suitable composition will gel in the upper alimentary canal, owing to the presence of cations in the mucosal and salivary fluids. The liquid compositions containing pectin or gellan will typically consist of 0.01-20% w/v of the pectin or gellan in water or an aqueous buffer system.

30

Other useful compositions which promote mucoadhesion and prolonged therapeutic retention in the upper alimentary canal are colloidal dispersions containing 2-50% colloidal particles such as silica or titanium dioxide. Such formulations form as a flowable liquid with low viscosity suitable as a mouthwash or for generating a fine mist. However, the particles interact with glycoprotein, especially mucin, transforming the liquid into a viscous gel, providing effective mucoadhesion (e.g., U.S. Patent Nos. 5,993,846 and 6,319,513).

#### Bioerodable Film Delivery Devices

10       The most simple bioerodable devices contain the therapeutic agent(s) incorporated into a solid, usually lipid-containing, film or tablet. The device is formulated to remain solid at room temperature, but melt at body temperature, releasing the incorporated therapeutics. Suitable formulations of this type include, for example, cocoa butter.

15       Polymeric film devices provide several advantages for therapeutic delivery to the oral cavity. Unlike rinses, pastes, gels, and other flowable compositions, a film device can reside for prolonged periods of time (i.e., hours to days) in the oral cavity and provide sustained release throughout its residency. Typically, the film is partially or completely bioerodable and contains a mucoadhesive layer to  
20 fasten the film to the oral mucosa. Film devices, in addition to its use for delivering therapeutics, can also provide protection against mechanical injury or microbial infection of a lesion site. This physical barrier function is particularly advantageous when treating conditions such as mucositis or aphthous stomatitis. Additionally, as discussed further below, a film device can be used to release  
25 trefoil peptide therapy directly onto the underlying mucosa, into the lumen of the oral cavity, or a combination of both.

Film devices consist of at least two layers; a mucoadhesive layer suitable for attaching the film to the oral mucosa and a bulk layer which contains the active therapeutic(s). Many suitable mucoadhesives are known in the art and are  
30 discussed above. Optionally, one or more therapeutics can also be provided in the

adhesive layer.

The bulk layer of the composite delivery device may be made of one or more bioerodable polymeric materials. Suitable polymers include, for example, starch, gelatin, polyethylene glycol, polypropylene glycol, polyethylene oxide, 5 copolymers of ethylene oxide and propylene oxide, copolymers of polyethylene glycol and polypropylene glycol, polytetramethylene glycol, polyether urethane, hydroxyethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, alginate, collagen, polylactide, poly(lactide-co-glycolide) (PLGA), calcium polycarbophil, polyethylmethacrylate, cellulose 10 acetate, propylene glycol, polyacrylic acid, crosslinked polyacrylic acid, hydroxyethyl methacrylate/methyl methacrylate copolymer, silicon/ethyl cellulose/polyethylene glycol, urethane polyacrylate, polystyrene, polysulfone, polycarbonate, polyorthoesters, polyanhydrides, poly(amino acids), partially and completely hydrolyzed alkylene-vinyl acetate copolymers, polyvinyl chloride, 15 polymers of polyvinyl acetate, polyvinyl alkyl ethers, styrene acrylonitrile copolymers, poly(ethylene terphthalate), polyalkylenes, poly(vinyl imidazole), polyesters and combinations of two or more of these polymers.

A particularly useful bulk layer polymer consists of PLGA and ethyl cellulose. PLGA is bioerodable and can be formulated to degrade over a wide 20 range of conditions and rates. Ethyl cellulose is a water-insoluble polymer that can act as a plasticizer for the PLGA when a film is formed, but will be eroded in a bodily fluid. Due to its water-insolubility, it also has an effect on the degree and rate of swelling of the resultant film.

An optional third layer which is impermeable to the trefoil peptide can also 25 be added to the wafer. Preferably, this barrier layer is also bioerodable. Suitable barrier layer polymers include ethyl cellulose, poly(acrylic acid), or other polyelectrolytes. In one configuration, the barrier layer is placed on the opposite side of the bulk layer relative to the adhesive layer, thereby directing the released therapeutic agent onto the contacted epithelium rather than being diluted in the 30 lumenal fluid. This configuration is particularly useful for treating discrete

lesions (i.e., mucositis or aphthous stomatitis) of the tongue, sublingual tissue, or buccal mucosa. In an alternative configuration of the film device, the barrier layer is placed between the bulk layer and the adhesive layer. This configuration directs therapeutic release into the lumen of the oral cavity and is useful for  
5 treating more diffuse lesions of the tongue, oral cavity, and esophagus. The configuration is also useful for delivering therapeutics which are cytotoxic when administered at high concentrations because it has the effect of shielding the underlying tissue from direct contact with the therapeutic-containing film.

10 Chewable Tablets, Lozenges, and Confectionaries

Preparing a trefoil peptide-containing composition as a chewable tablet, lozenge, or a confectionary such as chewing gum provides several advantages to traditional drug delivery vehicles. First, prolonged contact and sustained release at the target site (mouth and esophagus) is achieved. Second, such formulations  
15 often results in higher patient compliance, especially when administering trefoil peptides to children.

Formulations for chewable tablets are well known and typically contain a base of sugar, starch, or lipid and a flavoring agent. An exemplary formulation for a chewable tablet is provided below.

20 *Chewable ITF Tablet Formulation (per tablet)*

Intestinal trefoil factor – 300 mg  
Mannitol – 675 mg  
Microcrystalline cellulose – 75mg  
Corn starch – 30 mg  
25 Calcium sterate – 22 mg  
Flavoring Agent (i.e., sodium saccharin or peppermint oil)

The incorporation of therapeutics into chewing gum and other confectionary style formulations is known in the art (e.g., U.S. Patent No.  
30 5,858,391).

*Therapeutics Agents*Trefoil Peptides

- In preferred embodiments, the trefoil peptide is a human trefoil peptide. More preferably, it is human intestinal trefoil factor (ITF), spasmolytic 5 polypeptide (SP), or pS2. Most preferably, the trefoil peptide is human ITF.
- The trefoil peptides are present in the compositions of the invention at a concentration of between 0.1-1000 mg/ml, depending on the nature and condition of the lesion being treated, the anticipated frequency and duration of therapy, and the type of pharmaceutical composition used to deliver the trefoil peptide.
- 10 Typically, therapy is designed to deliver 0.1-500 mg of trefoil peptide per day to the patient.

Anti-Inflammatory Agents

- Any suitable anti-inflammatory agent can be formulated in the 15 compositions of the invention, at concentrations known for these agents. Many of the most useful anti-inflammatory agents also have analgesic and/or antipyretic properties. Anti-inflammatory agents suitable for co-formulation with a trefoil peptide include, for example, acetaminophen, aspirin (acetylsalicylic acid), ibuprofen, phenylbutazone, indomethacin, sulindac, diclofenac, and naproxen.

20

Antimicrobial Agents

- Any of the many known microbial agents can be used in the compositions of the invention at concentrations generally used for these agents. Antimicrobial agents include antibacterials, antifungals, antivirals, and other topical antiseptics.
- 25 Examples of antibacterial agents (antibiotics) include the penicillins (e.g., penicillin G, ampicillin, methicillin, oxacillin, and amoxicillin), the cephalosporins (e.g., cefadroxil, ceforanid, cefotaxime, and ceftriaxone), the tetracyclines (e.g., doxycycline, minocycline, and tetracycline), the aminoglycosides (e.g., amikacin, gentamycin, kanamycin, neomycin, 30 streptomycin, and tobramycin), the macrolides (e.g., azithromycin, clarithromycin,

and erythromycin), the fluoroquinolones (e.g., ciprofloxacin, lomefloxacin, and norfloxacin), and other antibiotics including chloramphenicol, clindamycin, cycloserine, isoniazid, rifampin, and vancomycin.

Antiviral agents are substances capable of destroying or suppressing the  
5 replication of viruses. Examples of anti-viral agents include 1,-D-ribofuranosyl-  
1,2,4-triazole-3 carboxamide, 9->2-hydroxy-ethoxy methylguanine,  
adamantanamine, 5-iodo-2'-deoxyuridine, trifluorothymidine, interferon, adenine  
arabinoside, protease inhibitors, thymidine kinase inhibitors, sugar or  
glycoprotein synthesis inhibitors, structural protein synthesis inhibitors,  
10 attachment and adsorption inhibitors, and nucleoside analogues such as acyclovir,  
penciclovir, valacyclovir, and ganciclovir.

Antifungal agents include both fungicidal and fungistatic agents such as,  
for example, amphotericin B, butylparaben, clindamycin, econazole, fluconazole,  
flucytosine, griseofulvin, nystatin, and ketoconazole.

15 Topical antiseptics include agents such as, for example, povidone-iodine  
and benzalkonium chloride.

#### Analgesics and Anesthetics

Any of the commonly used topical analgesics can be used in the  
20 compositions of the invention. The analgesic is present in an amount such that  
there is provided to the oral lesion a topical concentration of between one-half and  
five percent concentration for lidocaine (5-50 mg/ml in 20-40 ml per dose of  
liquid). Examples of other useful anesthetics include procaine, lidocaine,  
tetracaine, dibucaine, benzocaine, p-butylaminobenzoic acid 2-(diethylamino)  
25 ethyl ester HCl, mepivacaine, piperocaine, and dyclonine.

Other analgesics include opioids such as, for example, morphine, codeine,  
hydrocodone, and oxycodone. Any of these analgesics may also be co-formulated  
with other compounds having analgesic or anti-inflammatory properties, such as  
acetaminophen, aspirin, and ibuprofen.

Steroids

Steroids are commonly used to treat lesions of the upper alimentary canal.

For example, oral aphthous stomatitis is typically treated using a paste preparation of triamcinolone (0.1%), hydrocortisone, fluticasone, or beclomethasone.

5

*Conditions of the Upper Alimentary Canal Treated Using Trefoil Peptides*Mucositis

Mucositis is a common condition of the oral cavity which is characterized by inflammation of the mucous membranes. The condition is frequently caused  
10 by antineoplastic therapy, including chemotherapy and local radiation therapy.  
Symptoms of mucositis include ulcerations, redness, and swelling, and is  
associated with epithelial cell injury and death. Patients suffering from severe  
mucositis are susceptible to dehydration and malnutrition because mucositis pain  
limits dietary intake. In severe cases, mucositis can be so debilitating that patients  
15 may require prolonged hospitalization, parenteral nutrition, and narcotic pain  
medication. Additionally, destruction of the mucosal epithelium increases a  
patient's susceptibility to local and systemic infection. Disruption of the barrier  
function permits entry of microorganisms and microbial products normally  
retained in the gut lumen. Thus, pharmaceutical preparations which reduce the  
20 adverse effects associated with chemotherapy will improve the patient's quality of  
life, compliance with self-medication, and may permit administration of higher  
chemotherapeutic doses. Typically, mucositis is treated using a trefoil peptide-  
containing rinse or oral spray which the patient self-administers 1-5 times per  
day. The aqueous solution preferably contains a mucoadhesive and an anti-  
25 inflammatory agent. Other therapeutics, such as an topical analgesic agent (e.g.,  
lidocaine) may also be present. Alternatively, if the lesions are few in number and  
spatially localized, an intestinal trefoil peptide-containing film device an be  
placed directly over the lesions.

Tooth Extraction

Intestinal trefoil peptide-containing compositions of the invention are used to lessen complications and speed healing of the wound created by the extraction of a tooth. An oral rinse, paste, ointment, or gel, as described above, is applied to 5 the site of extraction immediately following the procedure and then 1-4 times per day, as needed, until epithelial regrowth is complete. Preferably, a topical analgesic is included in the formulation to relieve the temporary discomfort cause by the trauma of extraction. As a prophylactic measure, antibiotic agents may also be included in the formulation.

10

Gingivitis

Gingivitis is most commonly a chronic disease requiring ongoing treatment, in some cases for months or even years. The trefoil peptide-containing compositions of the invention can be employed to treat gingivitis, alone or in 15 conjunction with other treatments, particularly with an anti-microbial agent, and most commonly with an antibacterial agent. An oral intestinal trefoil peptide-containing rinse is swished in the patient's mouth at least once every 2-3 days, but as often as thrice daily, over a 3-4 week period, and the regimen is repeated as needed. Alternatively, the trefoil peptide is formulated into a gel or toothpaste. 20 In severe cases, a viscous gel or ointment having a high intestinal trefoil peptide concentration is applied directly to the wound via a plegget with a stick applicator.

Intestinal trefoil peptide-containing compositions can also be delivered in biodegradable drug delivery systems capable of formation of films applied below 25 the gum line (described in U.S. Patent Nos. 5,945,115 and 5,990,194. A biodegradable polymer, admixed with the intestinal trefoil peptide, is provided where the polymer can be injected in as a free-flowing solution below the gum line using a syringe. The polymer solution then, *in situ*, forms a solid biodegradable implant.

30

Aphthous Stomatitis

At the first indication of an outbreak of aphthous stomatitis (generally, the first twinge of pain), the patient swishes the mouth with an intestinal trefoil peptide-containing rinse, 1-4 times per day until the ulcer heals (generally 5-10 days). An intestinal trefoil peptide-containing gel can also be applied to the ulcer, in the same manner that steroid-containing gels are currently used. In addition, a gel can contain both an intestinal trefoil protein and a steroid known to be effective for aphthous stomatitis treatment. A direct application of more concentrated material can be directly applied to the wound via a pledget with a stick applicator. Alternatively, the lesion can be treated directly by applying a bioerodable film device containing both a trefoil peptide and a steroid (i.e., triamcinolone) directly to the lesion. Any formulation useful for treating aphthous stomatitis can also, optionally, contain a local anesthetic (i.e., lidocaine or benzocaine).

15

Behcet's Disease

Behcet's Disease is a rare, multi-system rheumatic disorder characterized by systemic vasculitis. One of the most frequent symptoms of Behcet's Disease is recurrent oral ulcerations which resemble aphthous lesions. Currently, treatment for Behcet's Disease is palliative, not curative. Thus, the intestinal trefoil peptides can be used to treat lesions of the upper alimentary canal in conjunction with currently available Behcet's Disease therapies including, for example, interferon alpha 2A and 2B, levamisole, cyclosporine, cyclophosphamide, and colchicine.

25

Oral Biopsy and Oral Surgery

In cases in which an oral neoplasm is suspected or known to be malignant, a biopsy or a curative resection is performed using a needle or a scalpel, resulting in an open wound. The surgical area, susceptible to infection and inflammation, is treated by rinsing with a trefoil peptide-containing solution 1-4 times per day.

Preferably, an analgesic, an anti-inflammatory, and an antibiotic are included in the formulation. Alternatively, a more concentrated gel, paste, or ointment may be directly applied to the lesion site. For post-operative treatment following resection of a malignancy, a topically active chemotherapeutic can be including in  
5 the trefoil peptide-containing composition.

#### Thermal and Chemical Burns

Trauma to the upper alimentary canal is frequently caused by exposure to excessive heat or noxious chemicals. Thermal burns to the upper alimentary canal  
10 are frequently mild in nature (i.e., first or second degree burns), resulting from the ingestion of overheated food or drink. More severe thermal burns of the oral mucosa and upper esophagus can be caused by inhalation of super heated air and are frequently observed in firefighters or victims of house or forest fires.

Chemical exposure can also damage the mucosa of the upper alimentary canal. Mild mucosal irritations and burns are often caused by ingestion of acidic food (i.e., fruits). More severe chemical burns are usually associated with  
15 accidental industrial or occupational exposures.

The intestinal trefoil peptide-containing pharmaceutical formulations described herein are useful for treating thermal and chemical burns of the upper alimentary canal. Preferably, viscous liquid or gel formulation containing a  
20 mucoadhesive is used to prolong mucosal exposure to the trefoil peptide.

Alternatively, a sustained release formulation, such as a bioerodable film, is used. Topical analgesics and antimicrobial agents are the most preferred secondary  
therapeutics to be co-administered.

25

#### *Production of Intestinal Trefoil Peptides*

Intestinal trefoil peptides can be produced by any method known in the art for expression of recombinant proteins. Nucleic acids that encode trefoil peptides (e.g., human intestinal trefoil factor (Figure 4 and 7), human pS2 (Figure 5 and 8),  
30 and human spasmolytic polypeptide (Figure 6 and 9) or fragments thereof may be

introduced into various cell types or cell-free systems for expression thereby allowing large-scale production, purification, and patient therapy.

Eukaryotic and prokaryotic trefoil peptide expression systems may be generated in which an intestinal trefoil peptide gene sequence is introduced into a 5 plasmid or other vector, which is then used to transform living cells. Constructs in which the intestinal trefoil peptide cDNA contains the entire open reading frame inserted in the correct orientation into an expression plasmid may be used for protein expression. Prokaryotic and eukaryotic expression systems allow for the expression and recovery of intestinal trefoil peptide fusion proteins in which 10 the trefoil peptide is covalently linked to a tag molecule which facilitates identification and/or purification. An enzymatic or chemical cleavage site can be engineered between the trefoil peptide and the tag molecule so that the tag can be removed following purification.

Typical expression vectors contain promoters that direct the synthesis of 15 large amounts of mRNA corresponding to the inserted intestinal trefoil peptide nucleic acid in the plasmid-bearing cells. They may also include a eukaryotic or prokaryotic origin of replication sequence allowing for their autonomous replication within the host organism, sequences that encode genetic traits that 20 allow vector-containing cells to be selected for in the presence of otherwise toxic drugs, and sequences that increase the efficiency with which the synthesized mRNA is translated. Stable long-term vectors may be maintained as freely replicating entities by using regulatory elements of, for example, viruses (e.g., the OriP sequences from the Epstein Barr Virus genome). Cell lines may also be produced that have integrated the vector into the genomic DNA, and in this 25 manner the gene product is produced on a continuous basis.

Expression of foreign sequences in bacteria, such as *Escherichia coli*, requires the insertion of an intestinal trefoil peptide nucleic acid sequence into a bacterial expression vector. Such plasmid vectors contain several elements required for the propagation of the plasmid in bacteria, and for expression of the 30 DNA inserted into the plasmid. Propagation of only plasmid-bearing bacteria is

achieved by introducing, into the plasmid, selectable marker-encoding sequences that allow plasmid-bearing bacteria to grow in the presence of otherwise toxic drugs. The plasmid also contains a transcriptional promoter capable of producing large amounts of mRNA from the cloned gene. Such promoters may be (but are 5 not necessarily) inducible promoters that initiate transcription upon induction. The plasmid also preferably contains a polylinker to simplify insertion of the gene in the correct orientation within the vector. Mammalian cells can also be used to express a trefoil peptide. Stable or transient cell line clones can be made using intestinal trefoil peptide expression vectors to produce the trefoil peptides in a 10 soluble (truncated and tagged) form. Appropriate cell lines include, for example, COS, HEK293T, CHO, or NIH cell lines.

Once the appropriate expression vectors are constructed, they are introduced into an appropriate host cell by transformation techniques, such as, but 15 not limited to, calcium phosphate transfection, DEAE-dextran transfection, electroporation, microinjection, protoplast fusion, or liposome-mediated transfection. The host cells that are transfected with the vectors of this invention may include (but are not limited to) *E. coli* or other bacteria, yeast, fungi, insect cells (using, for example, baculoviral vectors for expression in SF9 insect cells), or cells derived from mice, humans, or other animals. *In vitro* expression of 20 trefoil peptides, fusions, or polypeptide fragments encoded by cloned DNA may also be used. Those skilled in the art of molecular biology will understand that a wide variety of expression systems and purification systems may be used to produce recombinant trefoil peptides and fragments thereof. Some of these systems are described, for example, in Ausubel *et al.* (*Current Protocols in 25 Molecular Biology*, John Wiley & Sons, New York, NY 2000, hereby incorporated by reference).

Transgenic plants, plant cells and algae are also particularly useful for generating recombinant intestinal trefoil peptides for use in the methods and compositions of the invention. For example, transgenic tobacco plants or cultured 30 transgenic tobacco plant cells expressing an intestinal trefoil peptide can be

created using techniques known in the art (see, for example, U.S. Patent Nos. 5,202,422 and 6,140,075). Transgenic algae expression systems can also be used to produce recombinant intestinal trefoil peptides (see, for example, Chen et al., *Curr. Genet.* 39:365-370, 2001).

5 Once a recombinant protein is expressed, it can be isolated from cell lysates using protein purification techniques such as affinity chromatography. Once isolated, the recombinant protein can, if desired, be purified further by e.g., high performance liquid chromatography (HPLC; e.g., see Fisher, *Laboratory Techniques In Biochemistry And Molecular Biology*, Work and Burdon, Eds.,  
10 Elsevier, 1980).

Polypeptides of the invention, particularly short intestinal trefoil peptide fragments can also be produced by chemical synthesis using, for example, Merrifield solid phase synthesis, solution phase synthesis, or a combination of both (see, for example, the methods described in *Solid Phase Peptide Synthesis*,  
15 2nd ed., 1984, The Pierce Chemical Co., Rockford, IL). Optionally, peptide fragments are then be condensed by standard peptide assembly chemistry.

***Example 1: Mucositis Treatment for Patients Receiving Antineoplastic Therapy***

20 Trefoil peptide therapy is initiated prior to antineoplastic therapy (i.e., chemotherapy or radiation therapy), as a prophylactic to delay or prevent the onset of mucositis. Preferably, the patient begins intestinal trefoil peptide therapy three days prior to the first dose of antineoplastic therapy. During the prophylactic stage, the patient rinses the oral cavity with an intestinal trefoil peptide-containing  
25 solution. Alternatively, for convenience, the trefoil peptide is provided as a concentrated oral spray. Preferably, the patient swallows the solution, providing protection for the epithelial cells of the esophagus and lower gastrointestinal tract. Rinsing with and swallowing the intestinal trefoil peptide-containing solution continues at least twice daily until oral or esophageal mucositis is detected.

In patients with existing mucositis, epithelial healing is promoted using intestinal trefoil peptide therapy as described above. Palliative therapy is provided using benzocaine (a local anesthetic), and nystatin (an antifungal). The intestinal trefoil peptide can be co-formulated with the benzocaine and nystatin.

5 For example, the patient swishes an oral rinse solution (mouthwash), containing all therapeutic agents, 1-5 times each day. Alternatively, the trefoil peptide can be provided in a concentrated oral spray, with or without benzocaine and the nystatin is administered in an oral rinse.

The oral rinse solutions can either be swallowed or spit out. If swallowed, 10 an antacid may also be included in the formulation. Other useful therapeutics which provide palliative therapy include anti-inflammatories (e.g., ibuprofen) and other anti-microbial agents. Exemplary oral rinses useful for treating chemotherapy-induced mucositis are provided below, but are not intended to be limiting. A skilled physician or pharmacist will immediately recognize 15 appropriate substitutions, additions, and deletions that can be made to these formulations.

Rinse#1: Mix equal parts of:

- (i) diphenhydramine elixir (Benadryl®)
  - (ii) kaolin-pectin suspension (Kaopectate®)
  - 20 (iii) viscous lidocaine HCl (2%)
  - (iv) nystatin (oral suspension; 100,000 iu/ml)
  - (v) ITF (2.5 mg/ml)
- preferably swallowed after swishing

25 Rinse#2: Mix equal parts of:

- (i) diphenhydramine elixir (Benadryl®)
  - (ii) Maalox® (MgOH & AlOH; 40 mg/ml)
  - (iii) viscous lidocaine HCl (2%)
  - (iv) ITF (2.5 mg/ml)
- 30 preferably swallowed after swishing

*Other Embodiments*

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent  
5 application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without  
10 departing from the spirit or scope of the appended claims.

What is claimed is:

CLAIMS

1. A method for treating a lesion of the upper alimentary canal of a mammal comprising administering to said patient a therapeutically effective amount of an intestinal trefoil peptide.

5

2. The method of claim 1, wherein said intestinal trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor.

10 3. The method of claim 2, wherein said intestinal trefoil peptide is intestinal trefoil factor.

4. The method of claim 1, wherein said mammal is a human.

15 5. The method of claim 1, wherein said lesion is mucositis.

6. The method of claim 1, wherein said lesion is aphthous stomatitis.

7. The method of claim 1, wherein said lesion is caused by antineoplastic therapy.

20

8. The method of claim 7, wherein said antineoplastic therapy is radiation therapy.

25

9. The method of claim 7, wherein said antineoplastic therapy is chemotherapy.

10. The method of claim 1, wherein said lesion is the result of gingivitis.

30

11. The method of claim 1, wherein said lesion is the result of tooth extraction.

12. The method of claim 1, wherein said lesion is the result of a biopsy procedure or surgical intervention.

5        13. The method of claim 1, wherein said lesion is the result of tumor resection.

14. The method of claim 1, wherein said lesion is caused by thermal or chemical burn.

10

15. The method of claim 1, wherein said lesion is caused by Behcet's Disease.

16. The method of claim 1, wherein said lesion is caused by a bacterial, 15 viral, or fungal infection.

17. The method of claim 1, further comprising administering to said mammal a second therapeutic.

20        18. The method of claim 17, wherein said second therapeutic agent is an anti-inflammatory agent.

19. The method of claim 17, wherein said second therapeutic agent is an antibacterial agent.

25

20. The method of claim 19, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, or an aminoglycoside.

30        21. The method of claim 19, wherein said antibacterial agent is povidone-iodine.

22. The method of claim 17, wherein said second therapeutic agent is an anti-fungal agent.

5 23. The method of claim 22, wherein said anti-fungal agent is nystatin or Amphotericin B.

24. The method of claim 17, wherein said second therapeutic agent is an anti-viral agent.

10

25. The method of claim 24, wherein said anti-viral agent is acyclovir.

26. The method of claim 17, wherein said second therapeutic agent is an analgesic.

15

27. The method of claim 26, wherein said analgesic is lidocaine or benzocaine.

28. The method of claim 17, wherein said second therapeutic agent is a  
20 steroid.

29. The method of claim 28, wherein said steroid is triamcinolone or hydrocortisone.

25 30. The method of claim 17, wherein said trefoil peptide and said second therapeutic are administered in the same formulation.

31. The method of claim 17, wherein said trefoil peptide and said second therapeutic are administered in different formulations.

30

32. The method of claim 31, wherein said trefoil peptide and said second therapeutic are administered within 24 hours of each other.

33. The method of claim 32, wherein said trefoil peptide and said second therapeutic are administered within one hour of each other.  
5

34. A composition suitable for therapeutic delivery to the upper alimentary canal of a mammal, said composition comprising an intestinal trefoil peptide.

10 35. The composition of claim 34, wherein said intestinal trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor.

36. The composition of claim 35, wherein said intestinal trefoil peptide is intestinal trefoil factor.  
15

37. The composition of claim 34, wherein said composition is an oral spray.

20 38. The composition of claim 34, wherein said composition is an oral rinse.

39. The composition of claim 34, wherein said composition is a bioerodabile film.  
25

40. The composition of claim 34, wherein said composition comprises microspheres.

41. The composition of claim 37, 38, 39, or 40, wherein said composition further comprises a mucoadhesive agent.  
30

42. The composition of claim 34, wherein said composition is a chewing gum, lozenge, or chewable tablet.

43. The composition of claim 34, wherein said composition further  
5 comprises a second therapeutic agent.

44. The composition of claim 43, wherein said second therapeutic agent is an anti-inflammatory agent.

10 45. The composition of claim 43, wherein said second therapeutic agent is an antibacterial agent.

46. The composition of claim 45, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, or an aminoglycoside.

15 47. The composition of claim 45, wherein said antibacterial agent is povidone-iodine.

20 48. The composition of claim 43, wherein said second therapeutic agent is an anti-fungal agent.

49. The composition of claim 48, wherein said anti-fungal agent is nystatin or Amphotericin B.

25 50. The composition of claim 43, wherein said second therapeutic agent is an anti-viral agent.

51. The composition of claim 50, wherein said anti-viral agent is acyclovir.

52. The composition of claim 43, wherein said second therapeutic agent is an analgesic.

53. The composition of claim 52, wherein said analgesic is lidocaine or  
5 benzocaine.

54. The composition of claim 43, wherein said second therapeutic agent is a steroid.

10 55. The composition of claim 54, wherein said steroid is triamcinolone or hydrocortisone.

FIGURE 1

1 MLGLVLALLS SSSAEEYVGL SANQCAVPAK DRVDCGYPHV  
41 TPKECNRGC CFDSRIPGVP WCFKPLQEAE CTF

FIGURE 2

1 MATMENKVIC ALVLVSMAL GTLAEAQTET CTVAPRERQN  
41 CGFPGVTPSQ CANKGCCFDD TVRGVPWCFY PNTIDVPPEE  
81 ECEF

FIGURE 3

1 EKPSPCQCSR LSPHNRTNCG FPGITSDQCF DNGCCFDSSV  
41 TGVPWCFHPL PKQESDQCVM EVSDRRNCGY PGISPEECAS  
81 RKCCFSNFIF EVPWCFFPNS VEDCHY

FIGURE 4

1 atgctgggc tggcctggc cttgctgtcc tccagctctg ctgaggagta cgtggcctg  
61 tctgcaaacc agtgtgcgt gccagccaag gacagggtgg actgcggcta cccccatgtc  
121 accccccaagg agtgaacaa ccggggctgc tgcttgact ccaggatccc tggagtgcct  
181 tggtgttca agccctgca ggaagcagaa tgcaccttct ga

FIGURE 5

1 atggccacca tggagaacaa ggtgatctgc gccctggtcc tggtgtccat gctggccctc  
61 ggcaccctgg ccgaggccca gacagagacg tgtacagtgg ccccccgtga aagacagaat  
121 tgtggtttc ctgggtcac gccctccag tgtgcaaata agggctgctg tttcgacgac  
181 accgttcgtg gggccccctg gtgcttctat cctaatacca tcgacgtccc tccagaagag  
241 gagtgtgaat tttag

FIGURE 6

1 atgggacggc gagacgcccc gctcctggca gcgctcctcg tcctgggct atgtgccctg  
61 gcggggagtg agaaaccctc cccctgccag tgctccaggc tgagccccca taacaggacg  
121 aactgcggct tccctggaat caccagtgac cagttttg acaatggatg ctgttcgac  
181 tccagtgtca ctgggttccc ctggtgttcc cacccttcc caaagcaaga gtcggatcag  
241 tgcgtcatgg aggtctcaga ccgaagaaaac tgtggctacc cgggcatacg ccccgaggaa  
301 tgcgccttc ggaagtgctg cttctccaac ttcatcttg aagtgccctg gtgcttc  
361 ccgaagtctg tggaagactg ccattactaa

FIGURE 7

(page 1 of 2)

1 atgctggggc tggcctggc cttgctgtcc tccagctctg ctgaggagta cgtggccctg  
61 tgtgagact gcccgtactg cccccgtggc agggtggcg tgaaggaaag ggatccagga  
121 taagggggta ttctgcatttc attataataat ggccacactgt cacatataaca cttttccctg  
181 cgctagccct ttgaagtggg tctttattgt ccccatattca cagacaagga aaccgaggct  
241 cagagaaagt taacaactta tccaaggcag ccctgcccag tctgtgttga aatcagggtt  
301 tgagcctgag cccatccccat atgaccccat agccatctt gctggagatt tctaaattac  
361 aatataggtc tttatgcatt gttccacatt tacaaagaaa aaggaaagat gcaggagaaa  
421 aaccctgact tcagaacact gtcaataccg gcaggcacaa gggttcatatta gccattgcat  
481 agcaacccctg ccatggggtg tggctgctcc attaacccaa gtttgaagga atgagggcat  
541 ggcttttatac tgggtgttctt ctgagcaggg tcaaaggcag tggttcccgaa acttgcagcc  
601 cattagaatc acctggagag ctttaaaaat cctaattgtt ggggcacacc agttacatca  
661 gggcatctcc aggaagatc caggcctcag ctgttttgtt ttgagatagc cttgttttgt  
721 cactcactgc tggagtgcag tggcacaatc tcagctact gcaacccctcg cctctgggt  
781 tcaagcaatt cttgtgcctc ggcttcaagt agctgggatt acaggcatgc accaccatgc  
841 ccagctaatt ttttgattt ttagtagaga tggagtttcg ctatgttgc caagctggc  
901 tcaaactctt ggcctcaagt gatcctctcg ccttggcctc ccaaagtgtt ggaattacag  
961 gtgtaaagcca ccattggcccg ccaacgtcag tcatttttaa agctctgcag ctgattccag  
1021 tgtgagcgaa gtttggatgc caggaggata agcaattacg gactgggagc aagagaaggg  
1081 aatgtaaagac actgcacgtt attgccattt tcctaaggaa atactcagtt cgttaatgaa  
1141 acgcagtgaa cttctgtgc acatacagac atagaggctt gcctgaaaca tgaaaatatt  
1201 ggggactgaa ggatgtcccg ggagggtggg acatgctcaa caattcagga aggggagatg  
1261 cagaaaaaaag tgaaaagcag gcagcatgcg ttgcaatgtt ctctatggcg tgcctctc  
1321 ctgtcacggg tttcattttaa aacaaagggg caagggttttgg ttgtcaaac aatgaagggt  
1381 aactttgttt ctgggttcaa gggaccccgattcccccagg gggttctgc agctggaaagg  
1441 taccctaggc cgtatgtgac ttcccgagaa ggtgataaga gctgccaag gagaaagaca  
1501 cttaggcaaa tggccagagt ccccgagctg agcatttaac agactgcctc tctttaaata  
1561 ttcacaggga aagtgcattt tcctaagggc gagggtttca gcaagtggg aactcggcgg  
1621 ggtggggcgg agcggggagga tgcaaaacttg caaatgtaaag caaacacact caccgcagcc  
1681 cagcaaggcgc tctggcagct gacagggtt tgcgtggac agctgcaaac cagtgtggc  
1741 tgccagccaa ggacagggtg gactgcggct acccccatgt caccggcaag gagtgcaaca  
1801 accggggctg ctgttttgc tccaggatcc ctggagggttca ttgggttttc aagccctgc  
1861 aggaaggcagg taaggccccca gtggcatctgt ggtctggcc cagccccata aggcaggggg  
1921 tctcaggccc tccctgtctt ttctgggtcg gagatggagg cacaaggacc ccaggaagcc  
1981 acacacacac acctgttcca aggccctcaga gcagaggctt cacactttagg gcagccatgg  
2041 ccaggggctg tcctcttctg tcccctttat gtaaaaacata aaagcaattt tttcaaaaag  
2101 gtgttcaaaa tgatggcattt gcatagaggg aactgattt gtaactattt ttgagagaag  
2161 tggaaacgcgca taggtgtgaa aagccgggccc gactttggg ctgttttgc aaatcgcccc  
2221 cccagagctt tgtcattttgtt ggcattccctt acacagacgg caggcggtcc cagccctaga  
2281 cgtcaggcctt cgggtccaca ccccacctcc cccactctgc ccccccacaag ggtcatctcc  
2341 tctccctctc tctggcgtgg tggaggcag gtgcaggcga accaccctgg gggttccctc  
2401 cccaggggcg gagagectgc gtgcgtgc ggttaacagat ggccctgcac acgggtttgc  
2461 caccctgggtt ccaccaggt tagctgcctt acatcgtggg tggggcgatt ggctataagc  
2521 catctgcattt gtccaaagtgc cagctcagcc cccacgaagg cccgacccctgc gtgaggtacc  
2581 ttcctggAAC cagcatccag agggggctt cttggccctt tgccttagggt gaaatgcggg  
2641 aggctgagtc ctgtggccc cggctccctg atcaatgtt ggccctgccc caggccctcc

FIGURE 7

(page 2 of 2)

2701 cttcacccctc cccagcaagt ccagggtagg ggtgggggtg ggggtccaga gaaggccagg  
2761 agagagaggg gtctggctac tgtccactgc cggtccctgtt ctttcagctc cactggaact  
2821 acactctcct ctgagtgcc a cccatggccc tgccaaaggcc catctcgctt gttatctgcc  
2881 tgatccctgg gtcccactat cttgcttagc aaccggaggt gggaatcttg gctattcccc  
2941 catgtggtgg ggactcaaca cttcccggtg actctggga ggaggcagca ctaggtgctg  
3001 gccttggagc ctgcccgtac cttgggaagc tgggcagcgt gggtggagag agactgctca  
3061 cacaaggcctt tgctctgttt gcagaatgca cttctgagg cacctccagc tgccccggc  
3121 cggggatgc gaggctcgga gcaccctgc ccggctgtga ttgctgcag gcactgttca  
3181 tctcagcttt tctgtccctt tgctccggc aagegcttct gctgaaagtt catatctgga  
3241 gcctgatgtc ttaacgaata aaggcccattt gctccacccg

FIGURE 8

(page 1 of 2)

1 ccctgggtg cagctgagct agacatggga cggcgagacg cccagctcct ggcagcgctc  
61 ctcgtcctgg ggctatgtgc cctggcgggg agttagaaac cctgttaagt aaggagaggg  
121 tcttttatg tgcttcttt atttcttta aaaaaaaaaaaa aaaagcacaa ccataaatta  
181 acttgagagg gggaatggct ataaaggcat ctggcaatgt gtgttgtca catgggattt  
241 gccactgctc aggaggggtgg ctccaagaag ggcctccctc cttagggaaag gctgagtgac  
301 ggcaggtgtc agcggggcccc gtgtcgggcc aggagggcat tcccaccaag ggtccttgg  
361 gtcccagage actcacctct cgcctggatc ttggccttgg gtccatctgt tcaccctcct  
421 cttaggagggt tttgttttg ttttttccg agacaggatc tggctttgcc gcccaggcag  
481 gagtgcaagt gtgtgatctt ggctcaactgc aacctctgccc tcccaaggctc aagtgatcct  
541 cccacccctcag ccgcctgagt agctgaaacc acagggttgg accatcatgc cggccaaatt  
601 tttttttttt tattgtttgt agagatgggg tttcgacatg ttgcccagga tggctttgaa  
661 ctcctgagct caagaatct gcccgcctcg gcttcctaaa gtgtggat tataaggat  
721 agccaccatg cctgctttt tttttttt cctttaaac taatataaca atttcagcaa  
781 agccctatcg gcttcctcagg aggaaaccgc attgcttaaa tatgggcaag ataagactt  
841 gtgtttctt atgtggcaac aagacagtag aggcacatcccc tagaacctt gagagaagga  
901 gcagtgtggt ctgggttacc aggggtgggc cgactgaggg tctttccaca gccccctgccc  
961 agtgctccag gctgagcccc cataacagga cgaactgcgg cttcccttgg atcaccagtg  
1021 accagtgttt tgacaatggg tgctgtttcg actccagtgta cactgggtc ccctgggtt  
1081 tccacccctt cccaaagcaa ggtaatctt cagggaaatct tccctgggcca gcagctggca  
1141 acccaggacc cagttcaca ggcggagccc agagcagggg cggaggagg cccagttgtc  
1201 agtcttaggt tagctgggt gggtttagtct cgacttagcc cgggttgggt agtctggggc  
1261 tagcccaggt tggttagtct agagctagcc caggttgggt agtctggggc tagcccaggt  
1321 tggttagtct gggctagcc caggttgggt agtcttagggc tagttaggc tagttagtct  
1381 aaggctagcc caggttgggt agtttggagc tagcgcagg tggttagtct gggctagta  
1441 gcccaggttg gttagcctgg agctagccca ggttggtag tcttagggcta gcgtaggctg  
1501 gttagtctgg ggctagccca ggttggtag tcttaggacta gcccaggttg gttagtctgg  
1561 ggctagtagc ccaggttgg tagtctggg ctagcccaagg ttggtagtct tagggctag  
1621 gttagcttagt tagtcttaggg ctagcccaagg tttagttagt tggagctagc acaggtttag  
1681 tagtctgggg cttagtagcc aggttggtagt gtcggagct agcccaagtt gttagtctta  
1741 gggctagcat aggctggtagt gtcggggct agtagcttag gtttggtagt ctggagctag  
1801 cccaggttgg tttagtcttagg gtcagcttag gtcggtagt ctaggctag cccaggttgg  
1861 ttaatcgag ctagcccaagg ttggtagtct tggagctagc ccaggttgg tagtctggagg  
1921 cttagtagccc aggttggtagt gtcggggct agcccaagg tttagtctg gagctagcc  
1981 aggttggtagt gtcggagct agcccaagg tttagtctg ggactagcc ggactgctag  
2041 tctagaggtt gtcggaggtt ctggtagtct agaggttagt tagggctagc ccaggttgg  
2101 tagtctgggg cttagccatg ttggtagtct ttagactagc ctggactgtc agtcttagagg  
2161 tagcccaggt tggttagtct ggtactagcc tggactgttta gtcggaggtt agcccaagg  
2221 ggtaggttgg tttagtctgg gactgttagt cttagggtagt cccaggttgg  
2281 tttagtctggg actagcctgg actgttagt tagaggttagc ccagattgg tagtctggga  
2341 cttagtctgga ctgcttagtct agaggttagcc caggttggtagt gtcggggct cagctggac  
2401 tggttagtctta gaggttgggg aggttggtagt gtcggggct agtcttagt gtttacttt  
2461 gtttctacac tggttagtct ttcaacagac atgtgtgtgtt ggagccatca gtttacttt  
2521 agtttagaaa aaaatataataatataatgt aggttggtagt tagtttttga agtcttagt  
2581 ctgaagaagc ttccatgggg aaatgttagt atttatagg acagcagtaa cataagggt  
2641 gacagccctc aaatgttagg gaaggttagt aagccttcta gggttctttg ggagttagt

FIGURE 8

(page 2 of 2)

2701 ttatgttagt gcacgggatc aggacccaag ttgtaacgcc gacgagtgtc caaaggaagg  
2761 ttgtgtgtgt gtctgtcacc tttgtgcgtg gaaccaggca cgtccctctgg agaaggagga  
2821 ttcattccca agattgtgc tgggaggctt gctgggcccc gcagggaaac cagggatcg  
2881 gtggatttgtt cacgagcgcc cactgaatgg cagtgtctt gggaaatcaat accatgtcca  
2941 aacgcttccc atttaccaa ggtgcccaca aacctttct catcttgcc cgggggacca  
3001 ccccatattac tgagaacact gagtcccggag aggaaaaatg atttcccaa ggcggggac  
3061 tccagagctt ctgactgtga ccacccaca tgggccccac cttecgccggag gacaggccag  
3121 ccaagcgtcg ctggggccga cacttccaca gtccccgggg gaggcggtcc caggggcccga  
3181 cacttccaca gtccccgggg gaggccgtcc cgggggatgc tgccccagggc agcacctcat  
3241 gatccacgga ggctgcaaat cagcgctgtc ttcagaggag gaaggggtgg agctttccag  
3301 ggcacacgag ggctgactgg gtctcggtgc tttgtcctgtc ccatggcaga gtccggatcg  
3361 tgcgtcatgg aggtctcaga cccaaagaaaac tttgtggctacc cggggcatcg ccccgaggaa  
3421 tgcgccttc ggaagtgtcg cttctccaaac ttcattttgc aagtgcctgc gtgttcttc  
3481 ccgaagtcgt tggaaaggtaa cgtcgctgtc ggactctctg tctgggtttcc ggacaccatg  
3541 attcctcttc cgccgtaga ggtgggtgc agggaggggaa gctgcctcgc agcctcagtg  
3601 ccatcgagggc caggccccct gcctcctatg ggattctgaa ggcaattcca gaatgttctt  
3661 ggcaaagaca gcgtctttc aataagtta tagcctccag cattgccact gcgtcatctg  
3721 tggatggctt agaaacacgca gtcatccct gttgcctccc cagggtgtgc aacgttcaga  
3781 ggccgttgcct gttttattgc aagcccatct gcatttggag gtcactgagt gtcttgcact  
3841 gtgcgtggta ccagagaggg cccaaactcaa gcagacctgg ccccttc cgtggcttcc  
3901 ccgttctccc ccacatgacc ccgaatgaca aacccatcc acaacgttcc ttcctccacc cgttagtga  
3961 gtcccccggag ggtcccccggc gcagagggtga acgggtccac ttctccacc cgttagtga  
4021 tagtgtgttc ctgactcgga gtgtggcgtt gtaaaaaaaag accaagcaga tccaggaaaa  
4081 tggggaaaga gctactggcc cttgaaggat gccttttctt ttccctttgt taggatatca  
4141 aagcacttcca aagagcggaa tatttcatgt tcaggattt ccgagtgatt tttttatgt  
4201 gacctaagg tccacccatgg aaatgttcac ttgtctgggg agaatgcgc ccacagagga  
4261 aactctggcc tgggggtggga agatttggc ccttacacc ccctccccc gaaaggagct  
4321 ccttcttcag taggaagctc ctgggcaag tgatgcacgc ccacccagc ttgcagcc  
4381 aggcacttccc atttctgggg ttcccttacc aaccatcttgc catttaact tctagactgc  
4441 cattactaag agaggctgtt tccagaggat gcatctggct caccgggtgt tccaaacca  
4501 aagaagaaac ttgccttat cagcttcata cttcatgaaa ttctgggttt tcttaaccat  
4561 cttttcctca tttcaatgg tttaacatat aatttcttta aataaaaccc taaaatctg  
4621 ct

FIGURE 9

(page 1 of 2)

1 atccctgact cggggtcgccc tttggagcag agaggaggca atggccacca tggagaacaa  
 61 ggtgatctgc gcctggtcc tggtgtccat gctggccctc ggcaccctgg ccgaggccca  
 121 gacaggtaag gcgtgcttct tcctgctctg tggggccaca gccagctcg gcagcctccg  
 181 ccaggagcca ctgtttaca tacatatttt tgagcacctg ttttgtgcca ggtgctgttc  
 241 taggccccta aaagtatac caatttacag gatcggcaaa agcaggtgga gagtaactca  
 301 gggtggcagg gccccccggag accttcgaga agtgcacga ggaggggct gccttcagtc  
 361 ggggctgttt tcctgtgtta ggaagactat acaatcctcc caagtgtcat gttcaaaga  
 421 ggaagtgttgcgtgggat tcagaatagt gctttgact gttcatgcca acatctcccc  
 481 cagggggcaga ccctcccaag gcccattccag ataggccaa atgcccgtcc cagtgtggc  
 541 cacctgggag accctctccc acaggccca atgcccgtcc cagtgggtggc caactgggag  
 601 accctctccc acaggttccct gggctccctt gggatccatg ctctgggagt caaagccacc  
 661 tctctcatga gtgcgtggct ggcaacccat attccctggt gttgtcaagt ggatcggttg  
 721 ccctgggtcc ttcttagggag tggaggagga ggcattctt gttcccttgg gaagtgtttg  
 781 catctcaact cctttacctg cagaatggat caacggctcg cccttagggct gtcaagaaat  
 841 gctgtgtggc agcatctgcg acttgcacatt tgccagctgt ggggagctga ataacttatt  
 901 tgccgttatt aggtacagtt tcaagggtggg ggcaggagaa agggcttct acgtttccaa  
 961 agcaagggtt tccagagagg cctgaagagg gaggccccag tgggtgtgtc cgtccccca  
 1021 ctgccttcca gccaccttctt gatctctgtc gtggggtacc gggcctgagg ggtgggcttgc  
 1081 ggcagegttag aagagcagcc agcattggc tgcaagtgggaa agacccca gccatggca  
 1141 gggagcgggg gagctttgga accccagaga ggaagtggcc tcgggttaca gaacgaactg  
 1201 ggtgggtccc cgtgtggcc accccccaggg ccattctgcct ggccttgc cccacccca  
 1261 gccccccagct ctgccccctg tgctgtgggaa tcacagaggc cgtggcaaac tccctcccc  
 1321 accccacaca ccctctggct caaggctcag agcgttttgc cgggtcaactc agtccatga  
 1381 tcctgttaca actgaaatct agaaaattgt gattacagtt tagtgcattc gtgtgtggaa  
 1441 accatttcca ttatatttcca tcatgcgaca aagacaaagc ggggtggcaaa gacagagtct  
 1501 gccggaggca gagcaccggg gctggaaatc ttcccttctg aggagggaaac ccccccggacc  
 1561 cccaggatga tgatctccc tcaccacggg gcctcttttgc accccccacag tgtccccggg  
 1621 gtgggcgtat atcaccttca cgtcgcgatg gatccagacc ccaggaggcc aaggttcccc  
 1681 tggaaagctgc tggcagcgg gagctgaaca cggatcttc ccagcaagcc aggaacactt  
 1741 tctccaaaga catctcgagg cagtccctga tagcaaagca gacaagagaa cagccccctt  
 1801 cggcctcccc tggggcggcc tcacctgagc cagtgtggcc agactgagtt cctccctcc  
 1861 tatgccccaa ggcaggaca gggaccggag ggtgctctgg gctcccttttgc ccccttgc  
 1921 tgcaggctgt caaccaccag atcctaatacg tttgttttgc gggatcttgc atttccggaa  
 1981 gctcagagcc tgaagctcg tggttagaaac ctcttgcata agatcctcg gcagccccca  
 2041 gccagccccca tctgtccacg tgccttgc tctcttagatcc cttccctcac tgccctgttgc  
 2101 caagctgtt cacagctgtt accctctgtc ggctcccttgc agaccaccc accccgttct  
 2161 ctcacccatc ctgcaatggg tttccaccc tcgaacacac ctgggtctct ggaatggct  
 2221 ttggccatgc ggctccatct tcacctgttgc aaccccttcc tcagggaggc cccctgttgc  
 2281 tggtaacctt gcttgcatt ggcccttccg gggagtggcc tacccttgc gttaccctgg  
 2341 gcaccctggg acgatggct tgcgttgc tgcacatgtt cttgccttc tcctccatca  
 2401 gatccttaga ctctttttt ttttttttgc agatggatgc ttgtctgtc actcaggctg  
 2461 gagtgcaatg gtgcgtatctt ggctcaactac aacccctgc tcctgggttc aagtgattct  
 2521 cctgcctcag cctcccaagt agctgggatt acagacgtgt gccacaatgc ccgcctaatt  
 2581 ttttgttattt ttagtagaga tggggcttca ccattttgtt caggctggc ttgaactcct  
 2641 gacctaagt gattcacctc cttcagcctc ccaaagtgtc gggattacag gcatgagcct  
 2701 gggccccagat attagactc ttattaatga cttctcttgc tttaatttgc gggatctcttgc

FIGURE 9

(page 2 of 2)

2761 cacctggcac agtgcctggc ttttgcctatg ctagctccca ctttcgcattgc acacaaatgg  
2821 tgctcagtaa atatttatgt attgagtaaa attaataat catttgcattga aattaaaaaag  
2881 tgaataaaata agttaccttag aaagatgcaa agtccacaaa cctggggcac cttgcatttt  
2941 ccctgagcgt aatgtttgcac catcaggatg tgaggaccac gtctccctct catgcctga  
3001 gggttttata tccgcctcac tggacagttg ctgatgtcat tggagaagga agctggatgg  
3061 gtgtgtgcac gataaacatca aggaattcag cccacaactt actttgcattc ttacctgtgc  
3121 actttcagag acgtgtacag tggccccccg taaaaagacag aattgtggtt ttcctgggtgt  
3181 cacgcctcc cagtgtgcaa ataagggtcg ctgttcgac gacaccgttc gtgggtccc  
3241 ctggtgcttc tatcctaata ccacacgt ccctccagaa ggtatggct ttttatacga  
3301 tgggttctga agatttagaa ttagtttagaa aagtcatatta agactacaga ggctctgatc  
3361 agcatcacca gctatgcctt tacacagagt cacggccgcc agtgtgtgtg caatggggta  
3421 gcctgagtcg ggctgcattc aggtccagga atagaaaggc agggctaagg gacttggaa  
3481 gaaacctgat ttcccccccg cttctctca catctctaac caaaagcctg ggaagagcca  
3541 ctgttggtaa cgcttcttag cttgccttagg atagaggggg aaggcatgac gaaatctgaa  
3601 gacatttcat gtattcttt tttttttttt ttttggaaat ggagtctcgc tccggttgc  
3661 ctgagctgga gtgcataatggt gcgatcttgg ctcaactgcaa tctctgcctc ctgagttcaa  
3721 cctcagcttc ctagtagctg agattacagg tgtgtgccac tacgcccagc taaattttt  
3781 ttgtatTTT agtatacggcgggttccacc atgttggcca gaccgggtttt gaactcttga  
3841 cctcaggtga tctgcccgc tcagcctccc agagagctgg gattacaggc gtgagccacc  
3901 gtgccccggct gacagttcat gttttctaaa gaatgtgcct atggatactt taaagtaaaa  
3961 actctgtaat tgtttaatg tggaaagaaaa tgtttacct cactaaagca tcttttc  
4021 cctcccccttc acccctgttag aggagtgtga attttagaca cttctgcagg gatctgcctg  
4081 cttccctgacg cgggtccgc cccagcacgg tgatttagtcc cagagctcgg ctgccacctc  
4141 caccggacac ctcagacacgc cttctgcacgc tggcctcgg ctcacaacac agattgactg  
4201 ctctgacttt gactactcaa aattggccta aaaattaaaa gagatgcata tt

## SEQUENCE LISTING

<110> The General Hospital Corporation

<120> Methods and Compositions for Treating  
Oral and Esophageal Lesions

<130> 50206/002WO2

<150> US 60/286,240  
<151> 2001-04-24

<160> 9

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 73

<212> PRT

<213> Homo sapien

<400> 1

Met Leu Gly Leu Val Leu Ala Leu Leu Ser Ser Ser Ser Ala Glu Glu  
1 5 10 15  
Tyr Val Gly Leu Ser Ala Asn Gln Cys Ala Val Pro Ala Lys Asp Arg  
20 25 30  
Val Asp Cys Gly Tyr Pro His Val Thr Pro Lys Glu Cys Asn Asn Arg  
35 40 45  
Gly Cys Cys Phe Asp Ser Arg Ile Pro Gly Val Pro Trp Cys Phe Lys  
50 55 60  
Pro Leu Gln Glu Ala Glu Cys Thr Phe  
65 70

<210> 2

<211> 84

<212> PRT

<213> Homo sapien

<400> 2

Met Ala Thr Met Glu Asn Lys Val Ile Cys Ala Leu Val Leu Val Ser  
1 5 10 15  
Met Leu Ala Leu Gly Thr Leu Ala Glu Ala Gln Thr Glu Thr Cys Thr  
20 25 30  
Val Ala Pro Arg Glu Arg Gln Asn Cys Gly Phe Pro Gly Val Thr Pro  
35 40 45  
Ser Gln Cys Ala Asn Lys Gly Cys Cys Phe Asp Asp Thr Val Arg Gly  
50 55 60  
Val Pro Trp Cys Phe Tyr Pro Asn Thr Ile Asp Val Pro Pro Glu Glu  
65 70 75 80  
Glu Cys Glu Phe

<210> 3

<211> 106

<212> PRT  
<213> Homo sapien

<400> 3  
Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg  
1 5 10 15  
Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn  
20 25 30  
Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His  
35 40 45  
Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp  
50 55 60  
Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser  
65 70 75 80  
Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe  
85 90 95  
Phe Pro Asn Ser Val Glu Asp Cys His Tyr  
100 105

<210> 4  
<211> 222  
<212> DNA  
<213> Homo sapien

<400> 4  
atgctgggc tggcctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg 60  
tctgcaaacc agtgtccgt gccagccaag gacagggtgg actgcggcta ccccatgtc 120  
acccccaagg agtcaacaa cccgggctgc tgcttgact ccaggatccc tggagtgcct 180  
tggtgttca agccctgca ggaagcagaa tgcaccccttca ga 222

<210> 5  
<211> 255  
<212> DNA  
<213> Homo sapien

<400> 5  
atggccacca tggagaacaa ggtgatctgc gccctggtcc tggtgtccat gctggccctc 60  
ggcacccctgg ccgaggccca gacagagacg tgtacagtgg ccccccgtga aagacagaat 120  
tgtggtttc ctggtgtcac gccctccag tgtcaaata agggctgtg tttcgacgac 180  
accgttcgtg gggccccctg gtgttttat cctaatacca tcgacgtccc tccagaagag 240  
gagtgtgaat ttttag 255

<210> 6  
<211> 390  
<212> DNA  
<213> Homo sapien

<400> 6  
atgggacggc gagacgcccc gctcctggca gcgcctcctcg tcctgggct atgtgccctg 60  
gcggggagtg agaaaccctc cccctccag tgctccaggc tgagccccca taacaggacg 120  
aactgcggct tccctggaat caccagtgc cagtgtttt acaatggatg ctgttgcac 180  
tccagtgta ctggggtccc ctggtgttc cacccctcc caaagcaaga gtggatcag 240  
tgcgcatgg aggtctcaga ccgaagaaac tgtggctacc cgggcattcag ccccgaggaa 300  
tgcgccttc ggaagtgcgt cttctccaaac ttcatcttg aagtgcctg gtgcttctc 360  
ccgaagtctg tggaaagactg ccattactaa 390

<210> 7

<211> 3280  
<212> DNA  
<213> Homo sapien

<400> 7  
atgctgggc tggcctggc cttgtgtcc tcacagctcg ctgaggagta cggtggcctg 60  
tgtgactact gcccgtact ccccggtggc agggtggcg tgaaggaaag ggatccagga 120  
taaggggggta ttctgcattt attaataat ggccacctgt cacatataca cttttcctg 180  
cgcttagccct ttgaagtggg tctttattgt cccatttca cagacaagga aaccgaggct 240  
cagagaaagt taacaactt tccaaggcag ccctgcccag tctgtgtga aatcagggtt 300  
tgagcctgag cccatccccat atgaccccat agccatcttt gctggagatt tctaaattac 360  
aatataggtc ttatgcattt gttccacatt tacaaaagaaa aaggaaagat gcaggagaaa 420  
aaccctgact tcagaacact gtcaataccg gcaggcacaa ggttcatta gccattgcat 480  
agcaaccctg ccatgggtg tggctgtcc attaaccctt gttgaagga atgagggcat 540  
ggctttatc tgggtgtctt ctgagcaggg tcaaaggcag tggttcccg acttgcagcc 600  
cattagaatc acctggagag cttaaaaat cctaattgtt ggggcacacc agttacatca 660  
gggcattctcc aggcaagatc caggcctcag ctgtttttt ggggatagc ctgttttgt 720  
caactcactgc tggagtgcag tggcacaatc tcagctact gcaacccctg cctccctgggt 780  
tcaagcaattt cttgtgcctc ggcttcaagt agctggattt acaggcatgc accaccatgc 840  
ccagctaattt tttttggattt ttagtagaga tggagttcg ctatgttgc caagctggc 900  
tcaaactctt ggcctcaagt gatcctcctg ccttggcctc ccaaagtgtt ggaattacag 960  
gtgttaagcca ccatgcccag ccaacgtcag tcatttttaa agtctgcag ctgattccag 1020  
tgtgagcgaa gtttggatgc caggaggata agcaattacg gactggagc aagagaaggg 1080  
aatgttaagac actgcacgtg attgccattt tccataaggaa atactcattt cgttaatgaa 1140  
acgcagtgaa ctctgtctgc acatacagac atagaggctt gcctgaaaca tgaaaatatt 1200  
ggggactgaa ggatgtcccg ggagggtggg acatgctcaa caattcagga agggagatg 1260  
cagaaaaaaag tgaaaaggcag gcagcatgc ttgcaatgtt ctctatggcg tgcctctc 1320  
ctgtcacggg tttcatttaa aacaaaagggg caagggtttt ggggtcaaac aatgaagggt 1380  
aactttgttt ctgggttcaa gggacccag attcccccagg ggttccctgcc agctggaaagg 1440  
tacccagggtc cgtatgtac ttcccgagaa ggtgataaga gctgtccaaag gagaagaca 1500  
cttaggcaaa tggccagagt ccccgagctg agcatttaac agactgcctc tcttaaata 1560  
ttcacagggg aagtgcacgtc tccataaggc gagggtttca gcaacttgc aactcggcgg 1620  
ggtggggcgg agcggggagga tgcaaaactt gaaatgttcaag caaacacact caccgcagcc 1680  
cagcaaggcg tctggcagct gacagggtt gtcgtggac agctgcaaac cagtgtgcgg 1740  
tgccagccaa ggacagggtg gactgcgtt accccatgtt cacccttcaag gagtgcaaca 1800  
accggggctg ctgttttgc tccaggatcc ctggagtgc tgggttgc aagccctgc 1860  
aggaaggcagg taaggccccaa gtggcatctg ggtctggcc cagccctata aggcaggggg 1920  
tctcaggggcc tccctgtctt ttctgggtt gagatggagg cacaaggacc ccaggaagcc 1980  
acacacacac acctgttcca aggcctcaga gcagaggctt cacacttagg gcagccatgg 2040  
ccaggggtcg tccctttctg tcccttttat gtaaaaacata aaagcaattt tttcaaaaag 2100  
gtgttcaaaa tgatggcattt gcatagaggg aactgatttt gtaacttgc ttgagagaag 2160  
tggaaacgcg tagtgtgtgg aaggccggcc gactttttggg ctgttttgc aaatcgcccc 2220  
cccagagct tgcattttt ggcattccctt acacagacgg caggcgttcc cagccctaga 2280  
cgtcaggcctt cgggtccaca cccacccctt cccactctgc ccccccacaaag ggtcatactcc 2340  
tctcccttc tctggcgtgg tggagggtcg gtgcagggtt accaccctgg gggttccctc 2400  
cccaggggcg gagagcctc gtgctgtcg ggttacacat ggcctgcac acgggtttgc 2460  
caccctggct ccaccaggct tagtgccttcc acatcggtttt tggggcgatt ggctataagc 2520  
catctgcacat gtccaaagtgc cagtcagcc cccacacggg cccgcacctgc gtgaggtacc 2580  
ttcctggaaac cagcatcccg agggccctt cttggccctt gtccttaggtt gaaatgcggg 2640  
aggctgagtc ctgtggcccc cggctccctt atcaatgtat ggcctgcac acgggtttgc 2700  
cttcacccttc cccagcaagt ccagggttgg ggtgggggtt ggggtccaga gaaggccagg 2760  
agagagaggg gtctggctac tgcacttgc cggctctttt cttcagtc cacttgcact 2820  
acactcttctt ctgagtgcca gccatggccc tgccaaggcc catctgcattt gttatctgc 2880  
tgatccctgg gtcccactat cttgttttgc aaccggaggat gggaaatctt gctattcccc 2940  
catgtgggtt ggactcaaca ctccccgtt actctggggta ggaggcagca ctaggtgctg 3000  
gccttggagc ctggccctgac cttggggaaatc tggcagcgat ggggtggagag agactgctca 3060  
cacaaggctt tgctctgtttt gcagaatgtt ccttctgagg caccctccagc tgccccggc 3120  
cgggggatgc gaggctcgaa gcacccttgc ccggctgtga ttgctggccag gcactgttca 3180

tctcagcttt	tctgtccctt	tgctccggc	aaggcgcttct	gctgaaagtt	cataatctgga	3240
gcctgatgtc	ttaacgaata	aaggcccatt	gctccaccgg			3280
<210> 8						
<211> 4623						
<212> DNA						
<213> Homo sapien						
<400> 8						
dccctgggggt	gcagctgagc	tagacatggg	acggcgagac	gcccgactcc	tggcagcgct	60
cctcgctctg	gggcgtatgtg	ccctgggggg	gagttagaaaa	ccctgttaat	gaaggagagg	120
gtcttttat	gtgtttctt	tatttcttt	aaagaaaaaaa	aaaaagcaca	accataaatt	180
aacttgagag	ggggaatggc	tataaaggca	tctggcaatg	tgtgttgttc	acatgggatt	240
tgccactgt	caggagggtg	gctccaagaa	gggcctccct	cctaggaaaa	ggctgagtga	300
ggcgagggt	cagcggggccc	cgtgtcgggc	caggaggggca	ttccccaccaa	gggtccttgg	360
agtcccagag	cactcacctc	tcgcctggat	cttggccttg	ggtccatctg	ttcacccctcc	420
tctaggaggg	ttttgtttt	gttttttcc	gagacaggat	ctggctttgc	cgcccaggca	480
ggagtgcagt	gggtgtatct	tggctcaact	caacctctgc	ctcccaggct	caagtgatcc	540
tcccacaccta	gccccttag	tagtggaaac	cacagtgtg	gaccatcatg	cccgcccaat	600
ttttttttt	gtattgttt	tagagatggg	gtttcgacat	gttgcggcagg	atggtcttga	660
actcctgagc	tcaagcaatc	tgcccgccctc	ggcttcctaa	agtgcgtggg	ttataggtat	720
gagccaccaat	gcctggctt	ttttttttt	tcctttttaaa	ctaataataac	aatttcagca	780
aagccctatac	ggcttctcag	gaggaaacccg	cattgcttaa	atatggccaa	gataagactt	840
tgtgtttctc	tatgtggcaa	caagacagta	gaggcatccc	ctagaacctc	ttagagaaagg	900
agcagtgtgg	tctggggtac	cagggtgggg	ccgactgagg	gtctttccac	agccccctgc	960
cagtgcctca	ggctgagccc	ccataacagg	acgaactgcg	gctccctgg	aatcaccagt	1020
gaccagtgtt	ttgacaatgg	atgcttttc	gactccagtg	tcactgggt	cccttgggt	1080
ttccacccccc	tcccaaagca	aggtaatctt	ccagggaaatc	ttccctggcc	agcagctggc	1140
aaccaggagac	ccagcttcac	aggcggagcc	cagagcaggg	gccggaggag	gcccgatgtc	1200
tagtctaggg	ttagcctggg	tgggttagtc	ttagcttagc	cccggttgg	tagtctgggg	1260
ctagcccagg	ttggttagtc	tagagctagc	ccaggttgg	tagtctgggg	ctagcccagg	1320
ttggttagtc	tggggctagc	ccaggttgg	tagtcttaggg	ctagtgtagg	ctagttagtc	1380
taaggctagc	ccaggttgg	tagttggag	ctagcgcagg	ttggttagtc	tggggctagt	1440
agcccaggtt	ggttagcctg	gagctagccc	aggttggta	gtcttagggct	agcgtaggct	1500
ggttagctg	gggctagccc	aggttggta	gtctggagct	agcccaggtt	ggttagctg	1560
gggctagtag	cccaaggttgg	ttagtctggg	gctagccccag	gttggtagt	ctagggctag	1620
tgtaggctag	ttagtctagg	gctagccccag	gttagttagt	ttggagctag	cacaggttga	1680
ttagtctggg	gctagtagcc	taggttgg	agtctggagc	tagcccaagt	tgttagtct	1740
agggctagca	taggtctgg	agtctggggc	tagtagccct	gttttggtag	tctggagcta	1800
gcccaggtt	gtagtcttag	ggctagcgt	ggctgggttag	tctaggcgt	gcccgagggt	1860
gttaatcgga	gctagccccag	gttggtagt	ctggagctag	cccgagggtt	ttagtcttag	1920
gctagtagcc	caggttgg	agtctggggc	tagccagg	ttgttagtct	ggagctagcc	1980
caggttgg	agtctggagc	tagccagg	tggtagtct	gggactagcc	tggactgcta	2040
gtcttagaggt	agcttagaggg	actctagtc	tagaggtgt	ctaggcgt	cccagggttgg	2100
ttagtctggg	gctagccccat	gttggtagt	cttagactag	cctggactgc	tagtcttagag	2160
gtagcccagg	ttgttagtgc	tggtagtgc	ctggactgtt	agtctagagg	tagcccagg	2220
tggtagtgc	ggttagtctg	ggacttagtct	ggactgttag	tctagaggt	gcccgagggt	2280
gttagtctgg	gactagcctg	gactgttagt	ctagaggtag	cccagattgg	ttagtctggg	2340
actagtctgg	actgttagtc	tagaggtagc	ccaggttgg	tagctgggg	ccagcctgg	2400
ctgttagtct	agaggtaacc	caggtcagcc	aacagtgaga	tggagccatc	agtttactt	2460
tgtttctaca	ctgttagtgc	tttcaacaga	catgtgtgt	tggagccatc	agtttactt	2520
tagttgagaa	aaaaatataat	atataatata	tagtctctt	ctagttttt	aagtgtgact	2580
tctgaagaag	cttccatggg	gaaatgaagg	tatttaatag	gacagcagta	acataagggc	2640
tgacagccct	caaatgttag	ggaaggaagt	gaagccttct	agggttcttt	gggagtgagt	2700
tttatgttag	tgcacgggat	caggaccctaa	gtttaacacgc	cgacgagtgc	tcaaaggaaag	2760
gttgtgtgt	tgtcgtgcac	ctgtgtgcgt	ggaaccaggc	acgtccctcg	gagaaggagg	2820
attcatcccc	aagattgttg	ctgggaggct	tgctggggccc	cgcaggaaaa	ccaggcagat	2880
ggtggattgt	tcacgagcgc	ccactgaatg	gcagtgttct	tggaaatcaa	taccatgtcc	2940

aaacgcttc catcttacca aggtgccac aaacctttc tcatcttggc cggggggacc 3000  
 accccattn ctgagaacac tgagtcccgaa gaggcaaat gatttccca aggccccca 3060  
 ctccagagct tctgactgtg accacccac atggcccca cttcgccga ggacaggcca 3120  
 gccaaggcgtc gctggggccg acacttccac agtccccggg ggaggccgtc ccagggggccg 3180  
 acacttcac agtccccggg ggaggccgtc ccgggggatg ctgcggccagg cagcacctca 3240  
 tgatccacgg aggtgcaaa tcagcgtgc tctcagagga ggaagggtg gagcttcca 3300  
 gggcacagca ggctgactg ggtctcggtg ctgtgcctgt ccatggcag agtcggatca 3360  
 gtgcgtcatg gaggtctcag accgaagaaa ctgtggctac cccggccatca gcccggagga 3420  
 atgcgcctct cggaaagtgc gtttctccaa cttcatctt gaagtgcctt ggtcttctt 3480  
 cccgaagtct gtggaaaggta acgtcgctgt gggactctt ctgcgttcc cgacacccat 3540  
 gattcttcctt cggctccgtag aggtgggtg cagggagggg agtcgcctcg cagccctcagt 3600  
 gccatcgagg ccagggccccc tgcctcttat gggattctga aggcaatcc agaatgttct 3660  
 tggcaaagac agcgtcttt caataagttt atagcctca gcattgcac tgcgtcatct 3720  
 gtgatggctc tagaaacagc ggctcatccc tggcgttcc ccaggtgtt caacgtttag 3780  
 aggcggtgcc tggtttattt caagccatc tgcatttggg ggctactgag tgcttgcac 3840  
 tggctgggtt accagagagg gcccaactca agcagacctg gccccttctt ccgtggcttc 3900  
 cccgttctcc cccacatgac cccgaatgac aaacctcatc cacaacgtcc tgcgtccggc 3960  
 agtccccggg gggtcccggc ggcagaggtg aacgggtcca ctgcgttcc ccgttagtg 4020  
 atagtgtgtt cctgactcg agtgtggca ggtaaaaaaaaa gaccaaggcag atccaggaaa 4080  
 atggggaaag agctactggc ctttgaagga tgcctttctt ttccctttt taggatata 4140  
 aaagcactcc aaagagcgaa atatttcatg ttcaaggattt tccgagtgtat tttttttatg 4200  
 tgacctaag gtccacctag aaaatgttca cttgtctggg gagaatgcgc cccacagagg 4260  
 aaactctggc ctgggggtggg aagatttggt cccttacac cccctcccg ggaaaggagc 4320  
 tccttcttca gtaggaagct cctggggcaaa gtgtatgcacg cccacccag ctgcgttcc 4380  
 taggcactcc catttctggg gttcccttac caaccatctt gcatttaaac ttctagactg 4440  
 ccattactaa gagaggctgg ttccagagga tgcatttgc tcaccgggtt ttccgaaacc 4500  
 aaagaagaaa ctgcgttca tcaagttcat acttcatgaa atccctgggtt ttcttaacca 4560  
 tctttcttc attttcaatg gtttaacata taatttctt aaataaaacc cttaaaatct 4620  
 gct 4623

<210> 9  
 <211> 4252  
 <212> DNA  
 <213> Homo sapien

<400> 9  
 atccctgact cggggtcgcc tttggagcag agaggaggca atggccacca tggagaacaa 60  
 ggtgatctgc gccctggtcc tgggtccat gttggccctc ggcacctctgg ccgaggccca 120  
 gacaggttaag gcggtcttct tcctgctctg tggggccaca gccagctctg gcagcctccg 180  
 ccaggagcca ctgttttaca tacatatttt tgacacctg tttgttccca ggtgtgttcc 240  
 tagggccctta aaagtatatac caatttacag gatcgccaaa agcaggttga gagaactca 300  
 ggggtggcagg gccccccggag accttcgaga agtgcgcacg ggagggggct gccttcatgc 360  
 ggggctttt tcctgtgtt ggaagactat acaatctcc caagtgttcat gtttcaaaga 420  
 ggaagtttgc gctgtgggtt tcagaatagt gtttttactt gttcatggca acatctcccc 480  
 caggggcaga ccctcccaag gccccatccag ataggcccaa atgcgggtcc cagtgtatggc 540  
 cacctggggag accctctccc acagggccga atgcccgtcc cagtgggttgc caactggag 600  
 accctctctt acaggttctt gggctccctt gggatccatg ctctgggagt caaagccacc 660  
 tctctcatga gtgcgtggct ggcaaccat attccctgtt gttgtcaagt ggatcggtt 720  
 ccctgggtcc ttcttagggag tggaggagga ggcatttctt gttcccttgg gaagtgttt 780  
 catctcaact ccttacctg cagaatggat caacggctcg cccttagggct gtcaggaaat 840  
 gctgtgtggc agcatctgc acttgcactt tggcagctgt ggggagctga ataacttatt 900  
 tgccgttatt aggtacagtt tcaagggtgg ggcaggagaa agggcttctt acgtttccaa 960  
 agcaagggtt tccagagagg cctgaagagg gagcgcccgag tgggtctgtc cgtggccccc 1020  
 ctgccttca gccaccttctt gatctctgt gttgggtacc gggcctgagg gttgggtttg 1080  
 ggcagcgttag aagagcagcc agcattggc tgcgtggga agaccccca gccatggca 1140  
 gggagcgggg gagcttggg acccgagaga ggaagtggcc tgggtgtaca gaacgaactg 1200  
 ggtgggtccc cgtgtggcc acccccagggc ccatctgcct gcggcccttgc cccacccca 1260  
 gcccccaagct ctgccccctg tgctgtggga tcacagaggc cgtggcaaac tcccccccc 1320

accccacaca ccctctggct caaggctcag agcgttttgc cgggtcaactc aggtccatga 1380  
 tcctgttaca actgaaatct agaaaattgt gattacagtt tagtgcattc gtgtgtggaa 1440  
 accatTTcca ttatTTcca tcatgcgaca aagacaAAAGC gggTgggcaa gacagagtct 1500  
 gcccggaggca gagcacccggg gctggaaatc ttctcccttg aggagggaaac cccccccgacc 1560  
 cccaggatga tgatcctccc tcaccacggg gcctcttttgc acCCCCCACAG TGTCCCGGGG 1620  
 gtgggcgtat atcaccttca cgtcgcgtat gatccagacc ccaggaggGC aaggTTTCCA 1680  
 tggaaagctgc tggcagcggt gagctgaaaca cggatccttc ccagcaagcc aggaacactt 1740  
 tctccaaaga catctcgagg cagtcctga tagcaaagca gacaagagaa cagccccctct 1800  
 cggcctcccc tggggcgccc tcacctgagc cagtgtggcc agactgagtt cctcccttcc 1860  
 tatgccccaa ggcaggagca gggaccggag ggtgtctgg gctcttttgc acCCCCCTGC 1920  
 tgcaggctgt caaccacccat atccataag gttgttttgc gagaccttgc attccgegga 1980  
 gtcagagcc tgaagctcg gtgttagaac ctctgcata agatcctgcg cagccccca 2040  
 gccagccccca tctgtccacg tgccttcctc ctctagatcc cttecttcac tgcctgttt 2100  
 caagctgttt cacagttgtt accctctgtc ggctcttc acggaccccc acccggtct 2160  
 ctcaccttac ctgcaatggg ttccacccatc ctgaaacacac ctgggtctct ggaatggcct 2220  
 ttgcccattgc ggctccatct tcacctgggt aacctcttc tcagggagc cccctgtt 2280  
 tggtaacact gctgtcttc ggcctctccg gggagtgcgg taccgggtt gttaccctgg 2340  
 gcaccctggg acgatggcct tgcgttgtt cgcacatgtt ctgcctttc tcctccatca 2400  
 gatccttaga ctctttttt ttttttttgc agatggagtc ttgctctgtc actcaggctg 2460  
 gagtgcata gtcgtatctt ggctcaactac aacctctgc tcctgggttc aagtgtttct 2520  
 cctgcctcag cctcccaagt agctggatt acagacgtgt gccacaatgc ccgcctaatt 2580  
 ttttgttattt ttagtagaga tggggcttca ccattttgtt caggctggc ttgaaactcct 2640  
 gacctcaagt gattcacccatc ttgcacatc ccaaagtgtt gggattacag gcatgagcct 2700  
 gggcccaagat atttagactc ttatataatgc ttctctgtt ttaattttctt gggctctct 2760  
 cacctggcac agtgcctggc tttggccatg ctgatccca ctctcatgc acacaaatgg 2820  
 tgctcagtaa atatttatgtt attgagtaaa attaataat catttggta aattaaaaag 2880  
 tgaataaata agttaccttag aaagatgcaa agtccacaaa cctggggcac ctgcatttt 2940  
 ccctgagcgt aatgtttgca catcaggatg tgaggaccac gtctccctct catgtccatga 3000  
 gggtttata tccgcctcac tggacagttt ctgatgtcat tggagaagga agctggatgg 3060  
 gtgtgtgcata gataacatca aggaatttcag cccacaactt actttgttcc ttacctgtgc 3120  
 actttcagag acgtgtacag tggccccccatc tgaaagacag aattgtggtt ttctgtgtt 3180  
 cacggccccc cagtgcaaa ataagggttgc ctgtttcgac gacaccgttgc gtggggtccc 3240  
 ctgggtcttc tattctaata ccatcgacgt ccctccagaa ggtatggcct ttttatacga 3300  
 tgggttctga agatttagaa ttagtttagaa aagtcatatc agactacaga ggctctgtatc 3360  
 agcatcacca gctatgcctt tacacagatg cacggccgcgca agtgggtgtt caatggggta 3420  
 gcctgagtc ggctgcattc aggtccagga atagaaaggc agggctaagg gacttgggaa 3480  
 gaaacctgtat ttccccccggg cttctcttca catctctaac caaaaggctg ggaagagcca 3540  
 ctgttggtaa cgcttttagt ctgcctttagg atagaggggg aaggcatgac gaaatctgaa 3600  
 gacatttcata gtattttttt tttttttttt ttttggaaat ggagtctcgc tccggttgc 3660  
 ctgagctgga gtgcaatggt gcgatcttgc ctactgcac tctctgcctc ctgagttcaa 3720  
 ctcagcttc ttagtagctg agattacagg tgggtgtccac tacggccagc taaaattttttt 3780  
 ttgttattttt agtataagacg gggtttccacc atgttggccat gaccgggtttt gaactcttga 3840  
 ctcaggtgttgc tctggccgc tcaagcttcc agagagctgg gattacaggc gtgagccacc 3900  
 gtggcccggtt gacagttcat gttttctaaa gaatgtgcct atggataactt taaagttttttt 3960  
 actctgtat tggtaaatgc tgaaagaaaa tggttatccct cactaaagca tctctttctc 4020  
 cctcccccctc accccctgtat agagggtgtat attttagaca ctctgcagg gatctgcctg 4080  
 catctgcacg cgggtccgc cccagcacgg tgatttagtcc cagagctcg ctgcacccatc 4140  
 cacggacac ctcagacacg ctgcacatc cttctgcacg tggccttgc ctcacaacac agattgactg 4200  
 ctctgactttt gactactcaa aattggccatc aaaattttttt gagatcgata tt 4252

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US02/12891

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 38/00, 38/16  
US CL : 514/2, 12

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 514/2, 12; 435/69.1, 91, 172.3, 320.1, 235.1; 536/27, 23.5; 530/300; 935/9, 10, 23

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,E	US 6,221,840 B1 (PODOLSKY et al) 24 April 2001 (24.04.2001), abstract, column 1, lines 25-38, column 15, lines 33-47, column 16, lines 1-5, column 27 lines 14-35, column 28, lines 13-34.	1-6, 34-38, 42
X	US 6,063,755 A (PODOLSKY et al) 16 May 2000 (16.05.2000), abstract, column 1, lines 29-33, column 3, lines 61-67, column 9, lines 31-34, column 10, lines 1-3.	1-16, 34-38, 42
A	MODLIN et al. Trefoil Peptides: Mitogens, Motogens, or Mirages? J. Clin. Gastroenterol. 1997, Vol.25 (Suppl. 1), pages S94-S100.	1-7, 10-16

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

30 July 2002 (30.07.2002)

Date of mailing of the international search report

11 SEP 2002

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230

Authorized officer

B. Dell Chism

Telephone No. (703) 308-0196

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US02/12891

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-55 (in-part)

Remark on Protest

  

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

PCT/US02/12891

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

1. This International Preliminary Examining Authority has found greater than 1 invention claimed in the International Application covered by the claims indicated below:

This application contains more than one invention or group of inventions wherein the inventions or group of inventions consists of a method and a product:

Group I, claim(s) 1-55, drawn to methods of treatment by trefoil peptide and a second therapeutic and the composition for such treatment.

However, the first invention claims a method of treatment requiring a trefoil peptide and subsequently claims three peptides of similar function but are structurally different for use in the treatment scheme. One or more of the peptides is/are known in the art (i.e. intestinal trefoil factors) (U.S. Patent No. 6,063,755) and therefore lack a special technical feature. Applicant must elect one peptide of the three. Additionally, the first invention claims a second therapeutic for use in conjunction with one of the structurally different peptides, however, the applicant claims six different classes of compounds to represent the second therapeutic wherein the classes are further divided into subgroups of therapeutics. The applicant must elect one representative for the second therapeutic. Furthermore, the first invention claims formulations for the peptide and the second therapeutic as being the same or different. The applicant needs to elect one formulation as same or different one from the other. For explanation of possible combinations see below:

1. Trefoil peptides: [A] spasmolytic polypeptide; [B] pS2; [C] intestinal trefoil factor. Applicant will receive search for [A] or Applicant must pay additional for either or both [B] and [C].
2. Second Therapeutic:
  - a. anti-inflammatory;
  - b. Antibacterial agent; (i) penicillin, (ii) cephalosporin, (iii) tetracycline, (iv) aminoglycoside, or (v) povidoneiodine.
  - c. anti-fungal agent; (i) nystatin or (ii) Amphotericin B.
  - d. anti-viral agent;
  - e. analgesic; (i) lidocaine or (ii) benzocaine.
  - f. steroid; (i) triamcinolone or (ii) hydrocortisone.
3. As to each of (a) to (f), Applicant needs to elect from (a); after first member of group additional fees for each member are required.
3. Formulation:
  - a. same formulation
  - b. different formulation

As demonstrated by the itemization above, there are 78 possible combinations of methods. Additional fees are required for searches beyond the first member or each group above. If additional members are not chosen and the required fees paid for the additional members, the first member of each group only will be searched.

**Continuation of B. FIELDS SEARCHED Item 3:**

**INTERNATIONAL SEARCH REPORT**

PCT/US02/12891

STN, SCISEARCH, BIOSIS, WEST, MEDLINE, TREFOIL, INTESTINAL, PEPTIDE, FACTOR, INFLAMMATORY,  
BACTERIAL, FUNGAL, ANTI, VIRAL, ANALGESIC, STEROID, LESION, ALIMENTARY, INFLAMMATION